WO2009088192A2 - 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체 - Google Patents
세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체 Download PDFInfo
- Publication number
- WO2009088192A2 WO2009088192A2 PCT/KR2009/000031 KR2009000031W WO2009088192A2 WO 2009088192 A2 WO2009088192 A2 WO 2009088192A2 KR 2009000031 W KR2009000031 W KR 2009000031W WO 2009088192 A2 WO2009088192 A2 WO 2009088192A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- indol
- methyl
- phenyl
- amine
- dihydro
- Prior art date
Links
- 0 *c(cc1*)cc2c1[n]c(C(N)=S)c2 Chemical compound *c(cc1*)cc2c1[n]c(C(N)=S)c2 0.000 description 3
- KUWSBFLUHOFTGC-UHFFFAOYSA-N C(CC1)CC1Nc1cc(Oc2ccccc2)cc2c1[nH]c(-c1ccccn1)c2 Chemical compound C(CC1)CC1Nc1cc(Oc2ccccc2)cc2c1[nH]c(-c1ccccn1)c2 KUWSBFLUHOFTGC-UHFFFAOYSA-N 0.000 description 1
- CIPPXLTXIPGNSN-UHFFFAOYSA-N C(COCC1)C1Nc1cccc2c1[nH]c(-c1cnccn1)c2 Chemical compound C(COCC1)C1Nc1cccc2c1[nH]c(-c1cnccn1)c2 CIPPXLTXIPGNSN-UHFFFAOYSA-N 0.000 description 1
- JYVLXSWLEAQZNB-UHFFFAOYSA-N Cc(cc1NC2CCN(C)CC2)cc2c1[nH]c(-c1ccccn1)c2 Chemical compound Cc(cc1NC2CCN(C)CC2)cc2c1[nH]c(-c1ccccn1)c2 JYVLXSWLEAQZNB-UHFFFAOYSA-N 0.000 description 1
- UZRCNCPUOFYHRB-UHFFFAOYSA-N O=S1(CCN(Cc(cc2NC3CCOCC3)cc3c2[nH]c(-c2ccccc2)c3)CC1)=O Chemical compound O=S1(CCN(Cc(cc2NC3CCOCC3)cc3c2[nH]c(-c2ccccc2)c3)CC1)=O UZRCNCPUOFYHRB-UHFFFAOYSA-N 0.000 description 1
- IICWRYWJLJRTJG-UHFFFAOYSA-N O=S1(CCN(Cc(cc2NCC3CCOCC3)cc3c2[nH]c(-c2ccccc2)c3Br)CC1)=O Chemical compound O=S1(CCN(Cc(cc2NCC3CCOCC3)cc3c2[nH]c(-c2ccccc2)c3Br)CC1)=O IICWRYWJLJRTJG-UHFFFAOYSA-N 0.000 description 1
- NLNTWGBEWGJHRY-UHFFFAOYSA-N OC(CCC1N=C(c2cc(cc(cc3NC4CCCC4)Cl)c3[nH]2)SC1)=O Chemical compound OC(CCC1N=C(c2cc(cc(cc3NC4CCCC4)Cl)c3[nH]2)SC1)=O NLNTWGBEWGJHRY-UHFFFAOYSA-N 0.000 description 1
- MVSFJSJYGUKSPE-UHFFFAOYSA-N OCC1N=C(c2cc(cc(cc3NC4CCOCC4)Oc4cnccc4)c3[nH]2)SC1 Chemical compound OCC1N=C(c2cc(cc(cc3NC4CCOCC4)Oc4cnccc4)c3[nH]2)SC1 MVSFJSJYGUKSPE-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention provides a cell, tissue or organ preservative composition, preservation method and composition of an animal comprising the indole and indazole compounds represented by the formula (1), pharmaceutically acceptable salts or isomers thereof as active ingredients. It relates to a manufacturing method. More specifically, the indole and indazole compounds according to the invention have the effect of protecting animal cells, tissues and organs for transplantation and inhibiting damage during migration or storage. Furthermore, the indole and indazole compounds of the invention have the effect of protecting organs from damage by reperfusion in tissues or organs after transplantation.
- cryopreservation methods less than 20 degrees, generally 4 degrees Celsius
- Various preservatives have been developed and used clinically.
- indole and indazole compounds according to the present invention are medicinally very useful structures, and many studies have been reported on compounds having the indole structure as the parent nucleus.
- patent WO2006 / 112549 which is reported to be active against glucokinase
- patent WO2004 / 018428 which may be used as an antibiotic
- the present inventors develop a substance that extends the conventional shelf life and enhances the protective effect when preserving various tissues and organs or blood for organ transplantation by inhibiting necrosis of various animal cells, and further transplanting. Intensive and extensive research has been conducted to develop compounds for improving the function of organs. As a result, the indole and indazole derivatives represented by the formula (1) as described below show excellent effects and It was completed. Indole and indazole compounds according to the invention have already been disclosed and claimed by Korean applicants in Korean Patent Application Nos. 10-2007-0082687, 10-2008-0080519 and 10-2008-0080537.
- the present invention provides a cell, tissue of an animal characterized by containing an indole and indazole compound represented by the formula (1), a pharmaceutically acceptable salt or isomer thereof as an active ingredient together with a pharmaceutically acceptable carrier. Or an organ preservative composition.
- the invention also relates to a cell, tissue and organ preservative composition, specifically comprising mixing a compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof as an active ingredient with a pharmaceutically acceptable carrier,
- the present invention provides a method for preparing a composition for preventing damage caused by cryopreservation, transplant surgery, or reperfusion after transplantation of an organ, an independent cell system or tissue.
- the invention also relates to a cell, tissue or organ of an animal for use in transplanting a composition according to the invention comprising a compound of formula (1), a pharmaceutically acceptable salt or isomer thereof as an active ingredient Provide a method for preservation.
- composition according to the invention uses indole and indazole compounds of the formula (1), pharmaceutically acceptable salts or isomers thereof as active ingredients.
- X represents C or N
- n is 0 or 1
- n is 1 when X is C
- n is 0 when X is N
- A represents a direct bond, represents C 3 -C 8 -cycloalkyl, represents phenyl, or a 5-6 membered heteroaryl containing 1 to 3 heteroatoms each selected from N, O and S atoms or Represents a heterocycle,
- R1 represents hydrogen, -C (O) -B-X'-R7 or-(CR5R6) m -B-X'-R7,
- n 0 to 4
- R 5 and R 6 each independently represent hydrogen or C 1 -C 5 -alkyl
- B represents a direct bond, optionally represents C 3 -C 8 -cycloalkyl comprising oxo, or a 3 to 10 membered heterocycle including 1 to 3 heteroatoms each selected from O, S and N atoms or Heteroaryl,
- X ' represents a direct bond or -C (O)-, -SO 2- , -CO 2 -or -C (O) NR5-,
- R7 represents hydrogen, C 1 -C 6 -alkyl, halogeno-C 1 -C 6 -alkyl, halogen, (CR 5 R 6 ) m -phenyl, (CR 5 R 6) m -hydroxy or (CR 5 R 6) m -heterocycle, Wherein the heterocycle is a 3-10 membered ring optionally containing oxo and containing 1 to 3 heteroatoms selected from N, O and S atoms,
- R2 represents-(CR5R6) m -DX "-R8,
- D represents a direct bond or a 3-10 membered heterocycle or heteroaryl, each optionally including oxo and optionally fused and containing 1-4 heteroatoms selected from N, O and S atoms,
- X represents a direct bond or -C (O)-, -C (O) O-, -NR5C (O)-, -C (O) NR5- or -O-,
- R8 represents hydrogen, halogen, C 1 -C 6 -alkyl, halogeno-C 1 -C 6 -alkyl, tri (C 1 -C 6 -alkyl) silane or hydroxy-C 1 -C 6 -alkyl,
- R3 represents hydrogen, halogen, cyano, nitro, aryl-R9 or (CR5R6) m -D-R9,
- R9 represents hydrogen, halogen, C 1 -C 6 -alkyl, cyano, nitro or C 1 -C 6 -alkoxy,
- R4 represents-(CR5R6) m -YD-R10
- Y represents a direct bond, -C (O) O- or -O-,
- R 10 represents hydrogen, nitro, halogen, C 1 -C 6 -alkyl, carboxy-C 1 -C 6 -alkyl, aryl or —C (O) O—R 5,
- alkyl, alkoxy, aryl, cycloalkyl, heterocycle and heteroaryl may be optionally substituted, and the substituents are hydroxy, halogen, nitrile, amino, C 1 -C 6 -alkylamino, di (C 1 -C In the group consisting of 6 -alkyl) amino, C 1 -C 6 -alkyl, halogeno-C 1 -C 6 -alkyl, C 1 -C 6 -alkylsulfonyl, aryl-C 1 -C 6 -alkoxy and oxo One or more to be selected.
- alkyl means aliphatic hydrocarbon radicals.
- Alkyl may be "saturated alkyl” that does not include alkenyl or alkynyl moieties, or "unsaturated alkyl” that includes at least one alkenyl or alkynyl moiety.
- Alkenyl refers to a group containing at least one carbon-carbon double bond
- alkynyl refers to a group containing at least one carbon-carbon triple bond.
- Alkyl may be branched or straight chain, respectively, when used alone or in combination, such as alkoxy.
- Alkyl groups may have from 1 to 20 carbon atoms unless otherwise defined.
- the alkyl group may be a medium sized alkyl having 1 to 10 carbon atoms.
- the alkyl group may be lower alkyl having 1 to 6 carbon atoms.
- Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, ethenyl, propenyl, butenyl and the like.
- C 1 -C 4 -alkyl has 1 to 4 carbon atoms in the alkyl chain and consists of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl and t-butyl Is selected from the group.
- alkoxy means alkyloxy having 1 to 10 carbon atoms unless otherwise defined.
- cycloalkyl means a saturated aliphatic 3-10 membered ring unless otherwise defined.
- Typical cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- 'aryl' includes at least one ring having a shared pi electron field and includes, for example, a monocyclic or fused polycyclic (ie, rings that divide adjacent pairs of carbon atoms) groups. . That is, aryl in the present specification means a 4-10 membered, preferably 6-10 membered aromatic monocyclic or multicyclic ring including phenyl, naphthyl and the like unless otherwise defined.
- heteroaryl includes one to three heteroatoms selected from the group consisting of N, O and S atoms, unless otherwise defined, and benzo or C 3 -C 8 Aromatic 3 to 10 member, preferably 4 to 8 member, more preferably 5 to 6 membered ring which can be fused with cycloalkyl.
- Examples of monocyclic heteroaryl include thiazole, oxazole, thiophene, furan, pyrrole, imidazole, isoxazole, isothiazole, pyrazole, triazole, triazine, thiadiazole, tetrazole, oxadia Sol, pyridine, pyridazine, pyrimidine, pyrazine and similar groups, but is not limited thereto.
- bicyclic heteroaryls examples include indole, indolin, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzisoxazole, benzthiazole, benzthiadiazole, benztriazole, quinoline, isoquinoline, purine , Furypyridine and similar groups, but are not limited to these.
- heterocycle' includes one to three heteroatoms selected from the group consisting of N, O and S atoms, unless defined otherwise, and can be fused with benzo or C 3 -C 8 -cycloalkyl, saturated or 1 Or a 3 to 10 member, preferably 4 to 8 member, and more preferably a 5 to 6 membered ring containing two double bonds.
- heterocycles include pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, piperazine, hydrofuran and the like. However, it is not limited only to these.
- X represents C or N
- n is 0 or 1
- n is 1 when X is C
- n is 0 when X is N
- A represents a direct bond, represents phenyl, or represents a 5-6 membered heteroaryl or heterocycle comprising 1 to 3 heteroatoms each selected from N, O and S atoms,
- R1 represents hydrogen, -C (O) -B-X'-R7 or-(CR5R6) m -B-X'-R7,
- n 0 to 2
- R 5 and R 6 each independently represent hydrogen or C 1 -C 5 -alkyl
- B represents a direct bond, optionally containing oxo and optionally halogen substituted C 4 -C 7 -cycloalkyl, or 4 to 8 containing 1 to 3 heteroatoms each selected from O, S and N atoms A membered heterocycle or heteroaryl,
- X ' represents a direct bond or -C (O)-, -SO 2- , -CO 2 -or -C (O) NH-,
- R7 represents hydrogen, C 1 -C 6 -alkyl, halogeno-C 1 -C 6 -alkyl, halogen, (CR 5 R 6 ) m -phenyl, (CR 5 R 6) m -hydroxy, (CR 5 R 6) m -heterocycle, Wherein the heterocycle is a 4-8 membered ring optionally containing oxo and containing 1 to 3 heteroatoms selected from N, O and S atoms,
- R2 represents-(CR5R6) m -DX "-R8,
- D represents a direct bond or a 4-8 membered heterocycle or heteroaryl, each optionally including oxo and optionally fused and containing 1-4 heteroatoms selected from N, O and S atoms,
- X represents -C (O)-, -C (O) O-, -NR5C (O)-, -C (O) NR5- or -O-,
- R8 represents hydrogen, halogen, C 1 -C 6 -alkyl, halogeno-C 1 -C 6 -alkyl, tri (C 1 -C 6 -alkyl) silane or hydroxy-C 1 -C 6 -alkyl,
- R3 represents hydrogen, halogen, cyano, nitro, aryl-R9 or (CR5R6) m -D-R9,
- R9 represents hydrogen, halogen, C 1 -C 6 -alkyl, cyano, nitro or C 1 -C 6 -alkoxy,
- R4 represents-(CR5R6) m -YD-R10
- Y represents a direct bond, -C (O) O- or -O-,
- R 10 represents hydrogen, nitro, halogen, C 1 -C 6 -alkyl, carboxy-C 1 -C 6 -alkyl, aryl or —C (O) O—R 5.
- X is C or N, and the structure of the compound for each case may be represented by the following formula (1a) or (1b).
- Substituent A in the compound of formula (1) according to the invention is more preferably phenyl, pyridine, 1,4-pyrazine, 4,5-dihydro-thiazole, thiazole, 4,5-dihydrooxazole, [1,2,4] oxadiazole and [1,3,4] oxadiazole.
- Substituent R1 more preferably represents -C (O) -B-X'-R7 or-(CHR5) m- B-X'-R7, wherein m is 0 to 2 and R5 is C 1 -C 3 -alkyl, B represents a direct bond, or optionally represents oxo and optionally halogen substituted C 5 -C 6 -cycloalkyl, or 1 to 3 heteroatoms each selected from O, S and N atoms Represents a 5-6 membered heterocycle or heteroaryl comprising X 'represents a direct bond, or represents -C (O)-, -SO 2- , -CO 2 -or -C (O) NH- , R7 is hydrogen, C 1 -C 3 -alkyl, halogeno-C 1 -C 3 -alkyl, halogen, (CH 2 ) m -phenyl, (CH 2 ) m -hydroxy, (CH 2 )
- R1 is most preferably selected from the group consisting of cyclopentyl, cyclohexyl, piperidine, tetrahydropyran, oxocyclohexyl, pyrrolidine, difluorocyclohexyl and tetrahydrofuran
- R7 is most Preferably hydrogen, methyl, ethyl, isopropyl, benzyl, hydroxymethyl, (morpholin-4-yl) -ethyl, tetrahydrofuran, 2,2,2-trifluoroethyl, hydroxyethyl, 1, 1-dioxothiomorpholine, tetrahydropyran, (tetrahydropyran-4-yl) -methyl and trifluoromethyl.
- D in the substituent R2 more preferably represents a direct bond or is selected from the group consisting of piperazine, pyrrolidine, morpholine, 1,1-dioxothiomorpholine and oxopiperazine, and R8 is more preferably Is selected from the group consisting of hydrogen, ethyl, hydroxymethyl, methyl and fluorine.
- Substituent R3 more preferably represents hydrogen or halogen, represents phenyl optionally substituted by alkoxy, or contains 1 to 3 heteroatoms selected from N, S and O atoms as ring members and optionally comprises oxo 6-membered heterocyclylmethyl.
- R 3 is most preferably hydrogen, bromine, phenyl, methoxy-phenyl, morpholin-4-yl-methyl, oxopiperazin-4-yl-methyl, 1,1-dioxo-thiomorpholin-4-yl -Methyl is selected from the group consisting of.
- Substituent R4 more preferably represents-(CH 2 ) m -YD-R10, m is 0 to 2, Y represents a direct bond or -C (O) O- or -O-, D is Pyridine or optionally 5 to 6 membered heterocycle comprising oxo and containing 1 to 3 heteroatoms selected from N, S and O atoms, R 10 is hydrogen, halogen, C 1 -C 3 -alkyl,- (CH 2 ) —CO 2 H, aryl or —C (O) O—R 5, wherein R 5 represents hydrogen or C 1 -C 3 -alkyl.
- D in the substituent R4 is most preferably selected from the group consisting of 1,1-dioxo-thio-morpholine, oxopiperazine, pyridine, morpholine and 4,5-dihydro-thiazole, and R10 is most preferably Is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl, ethyl and-(CH 2 ) -CO 2 H.
- Representative compounds of formula (1) according to the present invention include the following compounds:
- the compounds of formula (1) according to the invention may also form pharmaceutically acceptable salts.
- Such pharmaceutically acceptable salts include acids that form non-toxic acid addition salts containing pharmaceutically acceptable anions, such as inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, and the like; Organic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, and the like; Acid addition salts formed by sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
- carboxylic acid salts include alkali metal or alkaline earth metal salts formed by lithium, sodium, potassium, calcium, magnesium, and the like; Amino acid salts such as lysine, arginine and guanidine; Organic salts such as dicyclohexylamine, N-methyl-D-glucamine, tris (hydroxymethyl) methylamine, diethanolamine, choline and triethylamine and the like.
- the compounds of formula (1) according to the invention can be converted into their salts by conventional methods.
- the compounds according to the invention may have asymmetric carbon center (s) and therefore may exist as R or S isomers, racemic compounds, diastereomeric mixtures and individual diastereomers, all of these isomers being within the scope of the invention. Included in
- the present invention also provides a process for preparing the compound of formula (1).
- a method for preparing a compound of formula (1) will be described based on exemplary reaction schemes to aid in understanding the present invention, but those skilled in the art to which the present invention pertains will be based on the structure of formula (1).
- Compounds of formula (1) may be prepared by various methods, all of which should be construed as being included in the scope of the present invention. That is, the compounds of formula (1) may be prepared by arbitrarily combining various synthesis methods described herein or disclosed in the prior art, which is understood to fall within the scope of the present invention, and the process for preparing the compound of formula (1) It is not limited to what is described.
- the compound of formula (1) may be prepared by reducing the nitro group of compound (2) according to the method of Scheme (1) below to prepare an amine compound (3), and introducing a substituent to the formed amine group.
- the compounds of formula (1) can be prepared by modifying the R3, R5, R6, and R7 substituents of compound (4) by the methods described in Schemes (2) to (8).
- a is Fe, Zn, or H 2 (Pd / C) and the like,
- b is an acylating agent in the form of R7-B-CO-W, wherein R7 and B are as defined in formula (1), and W is an OH or leaving group such as chloride, bromide, iodide, mixed Mixed anhydride and the like,
- c is a ketone in the form of R7-B ⁇ O or an aldehyde compound in the form of R7-B-CHO, sodium triacetoxyborohydride ⁇ NaBH (OAc) 3 ⁇ or sodium cyanoborohydride (NaBH 3 CN), and the like. ,
- R3 is as defined in formula (1)
- R 11 represents A-R 2 or CO 2 R 12, wherein A and R 2 are as defined in formula (1), R 12 represents C 1 -C 6 -alkyl,
- R4 is as defined in formula (1)
- R 1 is as defined in formula (1).
- Compound (2) can be manufactured by the method as described in following Reaction Formula (2)-(8).
- Compound (3) can be prepared by reducing Compound (2).
- the reduction reaction can be carried out using an acid catalyst and a metal or using a metal catalyst in the presence of hydrogen gas.
- Acids which can be used in the reduction reaction using an acid catalyst and a metal are, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, and the like, organic carbonic acids such as acetic acid and trifluoroacetic acid, amine salts such as ammonium chloride, and the like. Is hydrochloric acid, acetic acid or ammonium chloride and the like.
- the use amount of acid is conventionally 0.01-10 equivalents, preferably 0.1-5 equivalents to 1 equivalent of Compound (2).
- Metals which can be used are, for example, iron, zinc, lithium, sodium, tin (typically, tin chloride) and the like, and particularly preferably iron, zinc, tin chloride and the like.
- the use amount of metal is conventionally 1-20 equivalents, preferably 1-10 equivalents to 1 equivalent of Compound (2).
- the metal reaction in the presence of an acid catalyst can proceed in an inert solvent.
- inert solvents include alkyl alcohols such as methanol and ethanol, ethers such as tetrahydrofuran and diethyl ether, alkyl esters such as ethyl acetate, and the like, and preferably methanol, ethanol, tetrahydrofuran and ethyl acetate. to be.
- the reaction temperature is usually -10 to 200 degrees, preferably 25 to 120 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Metal catalysts that can be used in a reduction reaction using a metal catalyst in the presence of hydrogen gas are palladium, nickel, platinum, ruthenium, rhodium, and the like, and particularly preferably palladium, nickel and the like.
- the use amount of metal catalyst is conventionally 0.001-2 equivalents, preferably 0.01-1 equivalent to 1 equivalent of Compound (2).
- the pressure of the hydrogen gas is usually 1 to 10 atmospheres, preferably 1 to 3 atmospheres.
- the reaction may be performed in an inert solvent such as alkyl alcohols such as methanol and ethanol, ethers such as tetrahydrofuran and diethyl ether, alkyl acetates such as methyl acetate and ethyl acetate, and the like.
- the reaction proceeds in methanol, ethanol, ethyl acetate and the like.
- the temperature of the reaction using the metal catalyst is usually -10 to 200 degrees, preferably 25 to 50 degrees, the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (4) can be prepared through acylation or reductive alkylation of compound (3).
- the acylation reaction for the amine group of compound (3) can proceed using an acylating agent in the presence of a base.
- Bases that can be used are organic bases such as triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine and the like.
- the use amount of base is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (3).
- the use amount of acylating agent is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (3).
- the reaction can be carried out in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, chloroalkane such as dichloromethane, chloroform and the like, preferably dichloromethane, chloroform and the like.
- ether such as tetrahydrofuran
- diethyl ether chloroalkane
- chloroalkane such as dichloromethane, chloroform and the like, preferably dichloromethane, chloroform and the like.
- the reaction temperature is usually -10 to 100 degrees, preferably -10 to 50 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Reductive alkylation of the amine group of compound (3) can be carried out by reaction with an aldehyde or ketone using a reducing agent and an acid catalyst can be used if necessary.
- the amount of aldehyde or ketone is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (3).
- Reducing agents that can be used are sodium borohydride, sodium cyanoborohydride, sodium triacetoxy-borohydride and the like.
- the use amount of reducing agent is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (3).
- Acid catalysts that can be used are, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, and the like, organic carbonic acids such as acetic acid and trifluoroacetic acid, amine salts such as ammonium chloride, and the like, and particularly preferably hydrochloric acid, acetic acid and the like. to be.
- the use amount of acid is conventionally 0.1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (3).
- the reaction can be carried out in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, chloroalkane such as dichloromethane, chloroform, dichloroethane, and the like, preferably dichloroethane, chloroform and the like.
- ether such as tetrahydrofuran
- diethyl ether chloroalkane
- chloroalkane such as dichloromethane, chloroform, dichloroethane, and the like, preferably dichloroethane, chloroform and the like.
- the reaction temperature is usually -10 to 100 degrees, preferably -10 to 50 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- a is a metal hydroxide (eg, NaOH, LiOH),
- b is a binder (e.g., EDC, CDI, BOP-Cl),
- d is a metal catalyst (eg Pd / C, MnO 2 Etc) or BrCCl 3 Etc.
- e is a reducing agent (eg, NaBH 4 , LiAlH 4 ),
- f is I 2 or MsCl and the like
- R2 is as defined in formula (1)
- R4 is as defined in Scheme (1),
- R12 represents C 1 -C 6 -alkyl
- R13 means NO 2 or R1
- R14 represents p-MeOBn or Ph 3 C
- R 15 and R 16 each independently represent H, C 1 -C 6 -alkyl, 6-12 membered aryl or 5-12 membered heteroaryl, or R15 and R16 are linked to each other to form a 3-10 membered ring Can form
- R 15 represents H, C 1 -C 6 -alkyl, 6-12 membered aryl or 5-12 membered heteroaryl, R16 is absent,
- W is a leaving group, for example, halogen such as chloride, bromide, iodide or sulfonyl such as methanesulfonyl and p-toluenesulfonyl.
- halogen such as chloride, bromide, iodide or sulfonyl such as methanesulfonyl and p-toluenesulfonyl.
- Compound (5) can be produced by the method described in Scheme (7) or (8).
- Compound (6) can be prepared through the hydrolysis reaction of Compound (5) using a base.
- Bases that can be used are lithium hydroxide, sodium hydroxide, potassium hydroxide, metal bicarbonate, metal carbonate and the like.
- the use amount of base is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (5).
- the hydrolysis reaction can be performed in an inert solvent such as alkyl alcohols such as methanol and ethanol, ethers such as tetrahydrofuran and diethyl ether.
- the reaction temperature is usually -10 to 200 degrees, preferably 25 to 120 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (8) can be prepared through the coupling reaction between the carboxylic acid of compound (6) and the amine group of compound (7).
- Known binders that can be used in the coupling reaction include dicyclohexylcarbodiimide (DCC), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (EDC), 1,1'-dicarbonyldiimidazole Carbodiimides, such as (CDI), are used in a mixed state with 1-hydroxy-benzotriazole (HOBT) or 1-hydroxy-7-azabenzotriazole (HOAT), or bis- (2-oxo- 3-oxazolidinyl) -phosphonic acid chloride (BOP-Cl), diphenylphosphoryl azide (DPPA), N- [dimethylamino-1H-1,2,3-triazole [4,5-b]- Pyridin-1-ylmethylene] -N-methylmethane aluminum (HATU) and the like can be used
- the use amount of binder is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (6).
- the use amount of HOBT or HOAT used is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (5).
- hydrochloride salts of amines are used in the coupling reaction, the acid must be removed using a base.
- the base used at this time is an organic base such as triethylamine and diisopropylethylamine.
- the use amount of base is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (7).
- the coupling reaction can be carried out in an inert solvent tetrahydrofuran, diethyl ether, N, N-dimethylformamide, or the like.
- the reaction temperature is usually -10 to 200 degrees, preferably 25 to 120 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (9) is cyclized by compound (8) by the method described in Journal of Organic Chemistry, 68 (24), 2003, 9506-9509 and Tetrahedron, 55 (34), 1999, 10271-10282 and the like. It can manufacture.
- R14 is a p-methoxybenzyl ( p -MeOBn) group
- phosphorus pentachloride (PCl 5 ) is used to cyclize in a dichloromethane solvent.
- the use amount of PCl 5 is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (8).
- the reaction temperature is usually -10 to 50 degrees, preferably 0 to 25 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- R14 is a triphenylmethyl (Ph 3 C) group, it is cyclized in a dichloromethane solvent using trifluoromethanesulphonic-anhydride (Tf 2 O) and triphenylphosphine oxide (Ph 3 PO). .
- the use amount is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (8).
- the reaction temperature is usually -10 to 50 degrees, preferably 0 to 25 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (10) may be prepared by using a dehydrogenation reagent or a metal catalyst in Compound (9), or by sequentially introducing and removing a leaving group using a base.
- the dehydrogenation reagents are sulfur, selenium, various quinones (e.g., 2,3-dichloro-5,6-dicyano-benzoquizone (DDQ)) and the like.
- the dehydrogenation metal catalyst is palladium ( Usually, Pd / C), platinum, nickel (usually NiO 2 ), manganese (usually MnO 2 ), and the like.
- the use amount of dehydrogenation reagent is conventionally 1-20 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (9).
- the use amount of dehydrogenation metal catalyst is conventionally 0.001-10 equivalents, preferably 0.1-1 equivalent to 1 equivalent of Compound (9).
- Solvents used are benzene, toluene, decalin, quinoline and the like.
- the reaction temperature is usually 25 to 400 degrees, preferably 25 to 200 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Reagents used to introduce the leaving group include cupper (II) bromide (CuBr 2 ), bromotrichloromethane (BrCCl 3 ), N-bromosuccinimide (NBS), and the like amount is used in 1 equivalent of compound (9).
- Bases to be used include, for example, inorganic bases such as sodium carbonate, sodium bicarbonate, potassium carbonate, triethylamine, pyridine, 1,8-diazabicyclo [5,4,0] undeca-7-ene ( Organic bases, such as DBU), and sodium carbonate and DBU.
- the use amount of base is conventionally 0-10 equivalents, preferably 0-3 equivalents to 1 equivalent of Compound (9).
- Solvents used are inert solvents such as ethers such as tetrahydrofuran, diethyl ether, chloroalkanes such as dichloromethane, dichloroethane, chloroform and the like, preferably dichloromethane, chloroform and the like.
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 100 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (11) is prepared by hydrolysis reaction, reduction reaction, amine-acid coupling reaction, amine substitution reaction, etc. using the synthesis method of compounds (6), (15) and (16). can do.
- Compound (12) can be prepared through the hydrolysis reaction of Compound (9) using the synthesis method of Compound (6).
- Compound (14) can be prepared through the coupling reaction of carboxylic acid of Compound (12) with Compound (13) using the synthesis method of Compound (8).
- Compound (15) can be prepared by modifying the ester group of compound (9) with an alcohol group and introducing a leaving group X.
- Reducing agents used to reduce the ester groups to alcohol groups are, for example, sodium borohydride, lithium borohydride, borane, lithium aluminum hydride, diisobutyl aluminum hydride (DIBAL-H), and the like.
- the use amount of reducing agent is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (9).
- the reaction can be carried out in an inert solvent such as alcohol such as methanol or ethanol, ether such as tetrahydrofuran, diethyl ether or the like, preferably tetrahydrofuran, ether or the like.
- the reaction temperature is usually -78 to 100 degrees, preferably -10 to 50 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- the method of introducing the leaving group to the alcohol group is, for example, a halogenation or sulfonylation reaction.
- the halogenation reaction is imidazole using reagents such as iodine, bromine, N-iodosuccinimide (NIS), N-bromosuccinimide (NBS), carbon tetrachloride (CCl 4 ), carbon tetrabromide (CBr 4 ), and the like.
- base such as dimethylaminopyridine (DMAP) and phosphine such as triphenylphosphine (Ph 3 P) and tributylphosphine (Bu 3 P).
- the halogenating agent, base, and phosphine compound to be used are conventionally 1 to 10 equivalents, preferably 1 to 3 equivalents to 1 equivalent of Compound (9), respectively.
- the reaction proceeds in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, dichloromethane, chloroform, acetonitrile and the like.
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 50 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- the sulfonylation reaction can be carried out using a reagent such as methanesulfonyl chloride or p-toluenesulfonyl chloride under organic bases such as pyridine and triethylamine.
- the use amount of sulfonylating agent and base is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (9), respectively.
- the reaction can be performed in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, chloroalkane such as dichloromethane, dichloroethane, chloroform, and the like, preferably dichloromethane, dichloroethane and the like.
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 50 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (16) can be prepared through the coupling reaction of Compound (13) with Compound (15) using a base.
- the base include inorganic bases such as sodium carbonate, potassium carbonate and cesium carbonate, triethylamine, diisopropylethylamine, 1,8-diazabicyclo [5,4,0] undeca-7- Organic bases, such as ene (DBU), Preferably potassium carbonate, cesium carbonate, DBU, etc. can be used.
- the use amount of base is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (13).
- the reaction is carried out in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, alkylnitrile such as acetonitrile, propionitrile, amide such as N, N-dimethylformamide, preferably tetrahydrofuran , Acetonitrile, N, N-dimethylformamide and the like.
- ether such as tetrahydrofuran
- diethyl ether alkylnitrile
- amide such as N, N-dimethylformamide, preferably tetrahydrofuran , Acetonitrile, N, N-dimethylformamide and the like.
- the reaction temperature is usually -10 to 200 degrees, preferably 25 to 120 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- a is a binder (e.g., EDC, CDI, BOP-Cl),
- c is a metal hydroxide (eg, NaOH, LiOH),
- d is I 2 or MsCl and the like
- R4 is as defined in Scheme (1),
- R12, R13, R14, R15, R16 and Q are as defined in Scheme (2).
- Compound (18) can be prepared using Compound (6) and Compound (17) according to the synthesis method of Compound (8) in Scheme (2).
- Compound (19) can be prepared using Compound (18) according to the synthesis method of Compound (9) in Scheme (2).
- Compound (20) can be prepared using Compound (19) according to the synthesis method of Compound (6) in Scheme (2).
- Compound (21) can be prepared using Compound (20) according to the synthesis method of Compound (16) in Scheme (2).
- R2 is as defined in formula (1)
- R4 is as defined in Scheme (1),
- R13 is as defined in Scheme (2)
- W is a leaving group, for example, halogen such as chloride, bromide, iodide and the like, or sulfonyl such as methanesulfonyl, p-toluenesulfonyl and the like.
- Compound (22) can be prepared by modifying the carboxylic acid of Compound (6) to amide and then to thioamide using a Laensone reagent.
- the method for converting the carboxylic acid of the compound (6) into an amide is to make an acid chloride using cionyl chloride (SOCl 2 ) or oxalyl chloride ⁇ (COCl) 2 ⁇ and then react with ammonia water.
- the use amount of the cloning reagent used is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (6).
- the use amount of ammonia water is 1-5 equivalents normally.
- the reaction proceeds in an inert solvent dichloromethane, dichloroethane, chloroform and the like.
- the reaction temperature is usually -10 to 200 degrees, preferably -10 to 100 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Thioamide groups can be made by reacting an amide with a laensone reagent.
- the use amount of laensone reagent is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (6).
- the reaction is carried out in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, chloroalkane such as dichloromethane, dichloroethane, chloroform, aromatic hydrocarbons such as benzene, toluene, etc., preferably tetrahydrofuran, toluene, etc. You can proceed.
- the reaction temperature is usually -25 to 200 degrees, preferably 25 to 150 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (23) is typically a commercially available compound or can be prepared by known methods such as those described in WO199902501.
- Compound (24) can be manufactured by the coupling reaction of compound (22) and compound (23), and a base can be used as needed at this time.
- a base can be used as needed at this time.
- the base include inorganic bases such as sodium carbonate, potassium carbonate and cesium carbonate, organic bases such as diisopropylethylamine and DBU, and particularly preferably potassium carbonate and cesium carbonate.
- the use amount of base is conventionally 0-10 equivalents, preferably 0-5 equivalents to 1 equivalent of Compound (22).
- the reaction is carried out in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, alkylnitrile such as acetonitrile, propionitrile, amide such as N, N-dimethylformamide, preferably tetrahydrofuran , N, N-dimethylformamide and the like.
- ether such as tetrahydrofuran, diethyl ether
- alkylnitrile such as acetonitrile, propionitrile
- amide such as N, N-dimethylformamide, preferably tetrahydrofuran , N, N-dimethylformamide and the like.
- the reaction temperature is usually -10 to 200 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- a is an amine compound 25, a binder (e.g., EDC, CDI, BOP-Cl),
- c is a base (eg, K 2 CO 3 , Cs 2 CO 3 ),
- R2 is as defined in formula (1)
- R4 is as defined in Scheme (1),
- R13 is as defined in Scheme (2)
- W is a leaving group, for example halogen such as chloride, bromide, iodide or the like, or sulfonyl such as methanesulfonyl, p-toluenesulfonyl and the like.
- halogen such as chloride, bromide, iodide or the like
- sulfonyl such as methanesulfonyl, p-toluenesulfonyl and the like.
- Compound (25) is a commercially available compound or via a method known from Tetrahydron Letters, 28 (48), 6068-72, 1987, or Oragnic Process Research & Development 10 (3), 472-480, 2006. It can manufacture.
- Compound (26) can be prepared by sequentially proceeding amide synthesis and thioamide synthesis using a laensone reagent. Synthesis of the amide through the combination of the compound (6) and the compound (25) can be carried out using the method of making the amide compound (8) of Scheme (2), and the synthesis of the thioamide compound (26) is carried out It can proceed using the method of making compound (22).
- Compound (27) may be prepared through the cyclization reaction of Compound (26) using a base.
- Bases used are potassium carbonate, cesium carbonate, diisopropylethylamine, DBU and the like.
- the use amount of base is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (26).
- the reaction is carried out in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, alkyl nitrile such as acetonitrile, propionitrile, amide such as N, N-dimethylformamide, preferably tetrahydrofuran, It can proceed with acetonitrile, N, N- dimethylformamide, etc.
- the reaction temperature is usually -10 to 200 degrees, preferably 25 to 120 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- c is a binder (eg CDI, BOP-Cl) and compound (31),
- R2 is as defined in formula (1)
- R4 is as defined in Scheme (2)
- R12 and R13 are as defined in Scheme (2).
- Compound (28) can be prepared through the reaction of Compound (5) with hydrazine.
- the use amount of hydrazine is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (5).
- the reaction can be carried out in tetrahydrofuran, methanol, ethanol or the like which are inert solvents.
- the reaction temperature is usually -10 to 200 degrees, preferably 25 to 120 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (30) may be prepared by the coupling reaction of Compound (28) with Compound (29).
- An acid catalyst can be used as needed.
- the use amount of Compound (29) is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (28).
- the acid catalyst that can be used may be selected from, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, organic carbon acids such as acetic acid and trifluoroacetic acid, amine salts such as ammonium chloride, Lewis acids such as aluminum chloride, and the like. Can be.
- the use amount of acid is conventionally 0.001-5 equivalents, preferably 0.01-1 equivalent to 1 equivalent of Compound (29).
- the reaction may be carried out in an inert solvent, for example, ethers such as tetrahydrofuran, diethyl ether, aromatic hydrocarbons such as benzene, toluene, saturated hydrocarbons such as cyclohexane, hexane, and amides such as N, N-dimethylamide.
- ethers such as tetrahydrofuran, diethyl ether
- aromatic hydrocarbons such as benzene, toluene
- saturated hydrocarbons such as cyclohexane, hexane
- amides such as N, N-dimethylamide.
- Compound 31 is a commercially available compound or may be prepared by methods known in US 2004/0019215.
- Compound (32) can be prepared by sequentially performing the coupling reaction and dehydration reaction of Compound (6) and Compound (31).
- the use amount of binder used for the coupling reaction is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (6).
- the reaction can proceed in an inert solvent, tetrahydrofuran, N, N-dimethylamide.
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 50 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- the dehydration reaction that proceeds after the coupling reaction may optionally proceed with an acid catalyst. Proceed according to the method described for the preparation of compound (30).
- a is sodium nitrate (NaNO 2 ); Tin chloride (SnCl 2 ),
- b is a ketone compound (38), a base (for example NaOAc),
- c is an acid (eg, polyphosphate PPA),
- e is compound (42), a base (eg, NaOH),
- R3 is as defined in formula (1)
- R11, R4 and R12 are as defined in Scheme (1),
- R13 is as defined in Scheme (2).
- Compound 36 may be a commercially available compound or may be prepared by known methods such as Heterocycles, 68 (11), 2285-99, 2006, or Bioorganic & Medicinal Chemistry Letters, 14 (19), 4903-4906, 2004. .
- Compound (37) is a commercially available compound or can be made by modifying the amine group of compound (36) with a hydrazine group using known methods in the Journal of the America Chemical Society, 198 (48), 15374-75, 2006.
- the hydrazine compound 37 can be prepared by reducing with SnCl 2 without separating the diazonium salt 41 formed by reacting the amine group with NaNO 2 in the presence of hydrochloric acid.
- the amount of NaNO 2 used is conventionally 1-10 equivalents, preferably 2-5 equivalents to 1 equivalent of Compound (36).
- the use amount of SnCl 2 is conventionally 1-10 equivalents, preferably 2-5 equivalents to 1 equivalent of Compound (36).
- the reaction is carried out in an aqueous solution of 1-12N hydrochloric acid, preferably 4-8N hydrochloric acid.
- the reaction temperature is -10 to 50 degrees, the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 6 hours.
- Hydrazone compound (39) can be prepared through the coupling reaction of compound (37) and ketone compound (38). If compound (37) is in neutral form, no base is used. If acid salt form, base should be used to make neutral form.
- the base include organic metals such as metal hydroxides such as sodium hydroxide and lithium hydroxide, metal carbonates such as sodium bicarbonate and potassium carbonate and metal acetates such as sodium acetate, triethylamine and pyridine. A base etc. can be used and sodium acetate, sodium bicarbonate, etc. are preferable.
- the use amount of base is conventionally 1-5 equivalents, preferably 1-2 equivalents to 1 equivalent of Compound (37).
- the reaction can be carried out in tetrahydrofuran, methanol, ethanol or the like which are inert solvents.
- the reaction temperature is -10 to 100 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (39) was reacted with diazonium salt (41) and compound (42) in the presence of a base using the Japp-Klingemann rearrangement method described in Organic Process Research & Development, 2, 1988, 214-220. It can also manufacture.
- the use amount of hydrochloric acid used for the preparation of the diazonium salt 41 is conventionally 1-10 equivalents, preferably 2-4 equivalents to 1 equivalent of Compound (36).
- the base used for the reaction of the compounds (41) and (42) is sodium hydroxide, the amount of use is conventionally 1-20 equivalents, preferably 1-10 equivalents to 1 equivalent of Compound (42).
- a 50% aqueous ethanol solution is used as a solvent, and the reaction temperature is -10 to 50 degrees.
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound 40 may be prepared using an acid catalyst and compound 39.
- Acids used for the synthesis are polyphosphoric acid, hydrochloric acid, p-toluenesulfonic acid, sulfuric acid, acetic acid and the like, with polyphosphoric acid being preferred. Only polyphosphoric acid itself can be used, or it can mix and use with aromatic hydrocarbons, such as benzene and toluene.
- the reaction temperature is 25 to 150 degrees
- the reaction time is usually 5 minutes to 60 hours, preferably 5 minutes to 12 hours.
- Compound 42 is a commercially available compound or can be prepared by known methods, such as WO 2007040289, WO200601079 or Organic Letters 9 (3), 397-400, 2007.
- b is compound (44), Pd, Cu (I), Bu 4 NI, a base (eg, Et 3 N, Et 2 NH),
- c is a metal catalyst (eg Pd (II) or Cu (I) ⁇ or a base (eg KH or KOBu t ),
- d is trimethylsilylacetylene or 2-methyl-3-butyn-2-ol, Pd, Cu (I), a base (e.g., Et 3 N, Et 2 NH),
- e is tetrabutylammonium fluoride (Bu 4 NF) or NaOH,
- f is compound (48), Pd (II), Cu (I), a base (e.g., Et 3 N, Et 2 NH),
- R11 and R4 are as defined in Scheme (1),
- R13 is as defined in Scheme (2).
- Compound 36 may be a commercially available compound or may be prepared by known methods such as Heterocycles, 68 (11), 2285-99, 2006, or Bioorganic & Medicinal Chemistry Letters, 14 (19), 4903-4906, 2004. .
- Compound (43) can be prepared by the iodide reaction of compound (36).
- the iodide agent used in the iodide reaction may be selected from iodine, iodine monobromide, iodine monochloride, silver ions, for example, silver nitrate (AgNO 3 ), silver carbonate (AgCO 3 ), silver sulfate (Ag 2) SO 4 ) may be used together.
- the use amount of iodide is conventionally 1-10 equivalents, preferably 1-3 equivalents to 1 equivalent of Compound (36).
- the amount of silver ions used is 0 to 10 equivalents, preferably 0 to 3 equivalents.
- the reaction can be performed in an inert solvent such as ether such as tetrahydrofuran and diethyl ether, alkyl alcohols such as methanol and ethanol, alkyl nitrile such as acetonitrile and propionitrile, organic acids such as acetic acid and the like.
- ether such as tetrahydrofuran and diethyl ether
- alkyl alcohols such as methanol and ethanol
- alkyl nitrile such as acetonitrile and propionitrile
- organic acids such as acetic acid and the like.
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 50 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (44) is a commercially available compound or may be prepared by known methods such as Synthesis, 2004, 59-61 or Bioorganic & Medicinal Chemistry, 13, 2005, 197-209, or by the synthesis of compound 47, and the like. have.
- Compound (45) can be prepared by combining the iodine group of the compound (43) and the acetylene group of the compound (44) according to a known method in Tetrahedron, 59, 2003, 1571-1587.
- Coupling reactions include Pd (0) or Pd (II) catalysts ⁇ eg Pd (Ph 3 P) 4 , PdCl 2 (Ph 3 P) 2 ⁇ , Cu (I) catalysts (eg CuI) and base (For example, triethylamine, diethylamine, etc.) can be used.
- the amount of Pd catalyst used is conventionally 0.001-5 equivalents, preferably 0.01-1 equivalent to 1 equivalent of Compound (43).
- the amount of the Cu (I) catalyst to be used is usually 0.001 to 5 equivalents, preferably 0.01 to 1 equivalent to 1 equivalent of Compound (43).
- the use amount of base is conventionally 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (43).
- the reaction can proceed in an inert solvent such as ether such as tetrahydrofuran, diethyl ether, aromatic hydrocarbon such as benzene, toluene, N, N-dimethylformamide and the like.
- ether such as tetrahydrofuran
- diethyl ether aromatic hydrocarbon such as benzene, toluene, N, N-dimethylformamide and the like.
- the reaction temperature is usually -10 to 200 degrees, preferably 25 to 120 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (46) is described in JP2001 / 233855; Tetrahedron, 59, 2003, 1571-1587; Tetrahedron Letters, 47 (36), 2006, 6485-6388; Or Heterocycles, 64, 2004, 475 ⁇ 482, etc.] may be prepared by a cyclization reaction of the compound (45) according to a known method.
- the cyclization reaction can be carried out using a base, Cu (I), Pd (II) or the like.
- Bases that can be used are potassium hydride (KH), potassium thi-butoxide (KOBu t ), etc., and the amount of use is 1 to 10 equivalents, preferably 1 to 2 equivalents to 1 equivalent of Compound (45).
- the amount of Cu (I) and Pd (II) that can be used is 0.001 to 5 equivalents, preferably 0.01 to 1 equivalent, per 1 equivalent of Compound (45).
- the reaction is carried out in an inert solvent, for example, ethers such as tetrahydrofuran, diethyl ether, aromatic hydrocarbons such as benzene, toluene, alkyl nitriles such as acetonitrile, propionitrile, N, N-dimethylformamide, N -Methyl-pyrrolidinone (NMP) or the like.
- Preferred solvents are NMP when using a base, acetonitrile, toluene, N, N-dimethylformamide and the like when using Cu (I) or Pd (II).
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 120 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- compound (46) is a cyclization reaction using Pd (II) after changing the amine group of compound (43) to a trifluoroacetamide group according to a known method (Tetrahedron, 60, 2006, 10983 ⁇ 10992). It can be prepared through.
- Compound (47) is prepared through the coupling reaction of compound (43) with acetylene in the presence of Pd (II), Cu (I) and a base according to a known method of Journal of Organic Chemistry, 71, 2006, 167-175. can do.
- Acetylene used is trimethylsilylacetylene or 2-methyl-3-butyn-2-ol, and the amount used is 1 to 10 equivalents based on 1 equivalent of compound (43). Preferred is 1-3 equivalents.
- the use amount of Cu (I) and Pd (II) is 0.001-5 equivalents, respectively, preferably 0.01-1 equivalent to 1 equivalent of Compound (46).
- the base used is diethylamine, triethylamine, diisopropylethylamine and the like, the amount of use is 1 to 10 equivalents, preferably 1 to 5 equivalents to 1 equivalent of Compound (43).
- the reaction can proceed with an ether such as tetrahydrofuran, diethyl ether, which is an inert solvent, or an aromatic hydrocarbon such as benzene, toluene, or the like.
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 120 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound 48 is a commercially available compound or can be prepared using known methods, such as Journal of Organic Chemistry, 70, 2005, 6519-6522, Tetrahedron, 60 (48), 2004, 10983-10992.
- a is p-methoxybenzylchloride (PMBCl) or triphenylmethylchloride (TrCl), a base (eg NaOH),
- b is alkyl alcohol (eg methanol, ethanol), acetyl chloride or cionyl chloride,
- c is di-thi-butyloxy-dicarbonyl (Boc 2 O), a base (eg, NaOH, K 2 CO 3 ),
- d is alkylchloroformate (eg EtOCOCl), base (eg N-methylmorpholine),
- e is diazomethane (CH 2 N 2 ), a base (eg KOH),
- f is silver ions (e.g. silver benzoate),
- h is MsCl, Et 3 N,
- i is p-methoxybenzylthiol (PMBSH), NaH,
- R12 represents C 1 -C 6 -alkyl
- R14 represents p-MeOBn or Ph 3 C.
- Compound (49) can be prepared by protecting the thiol group of cysteine with p-methoxybenzylchloride (PMBCl) or triphenylmethylchloride (TrCl) in the presence of a base.
- PMBCl p-methoxybenzylchloride
- TrCl triphenylmethylchloride
- the amount of PMBCl or TrCl used in the protection reaction of thiol is 1 to 5 equivalents, preferably 1 to 2 equivalents to 1 equivalent of cysteine.
- Bases used are sodium hydroxide, potassium carbonate and the like, the amount used is 1 to 5 equivalents, preferably 1 to 2 equivalents to 1 equivalent of cysteine.
- the reaction can be carried out in tetrahydrofuran, methanol, ethanol, water and the like which are inert solvents.
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 50 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (51) can be prepared by protecting the amine group of Compound (49) with a BOC group.
- the amount of Boc 2 O used in the protection reaction of the amine is 1 to 5 equivalents, preferably 1 to 2 equivalents to 1 equivalent of cysteine.
- the base used may include hydroxides such as sodium hydroxide and lithium hydroxide, carbonates such as sodium carbonate, sodium bicarbonate, potassium carbonate and cesium carbonate, diisopropylethylamine and triethylamine. It is an organic base, Especially preferably, it is potassium carbonate, triethylamine, etc.
- the reaction can be carried out in tetrahydrofuran, methanol, ethanol, water and the like which are inert solvents.
- the reaction temperature is usually -10 to 200 degrees, preferably 0 to 50 degrees, and the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (50) can be prepared by esterifying the carboxyl group of Compound (49).
- the esterification reaction can be carried out using acetyl chloride or thionyl chloride in an alkyl alcohol solvent.
- the amount of acetyl chloride or thionyl chloride used is 1-10 equivalents, preferably 1-5 equivalents to 1 equivalent of Compound (49).
- the reaction temperature is usually 25 to 200 degrees, preferably 25 to 100 degrees
- the reaction time is usually 10 minutes to 60 hours, preferably 10 minutes to 12 hours.
- Compound (52) can be prepared by a known method in Helvetica Chimica Acta, 87, 2004, 3131 to 3159.
- Compound (51) is 1-2 equivalents of ethylchloroformate in the presence of 1-2 equivalents of base (e.g., N-methylmorpholine (NMM), triethylamine, etc.) in a tetrahydrofuran solvent at room temperature. (EtOCOCl) or isobutylchloroformate ( i BuOCOCl) to produce an unhydride compound.
- base e.g., N-methylmorpholine (NMM), triethylamine, etc.
- EtOCOCl N-methylmorpholine
- i BuOCOCl isobutylchloroformate
- Compound (52) can be prepared by reacting a BOC protecting group of the prepared compound with an acid (eg hydrochloric acid, trifluoroacetic acid) in a solvent such as dioxane or tetrahydrofuran, dichloromethane at room temperature.
- an acid eg hydrochloric acid, trifluoroacetic acid
- a solvent such as dioxane or tetrahydrofuran, dichloromethane at room temperature.
- Compound (53) is known as a starting material using glutamic acid or aspartic acid (Synlett, 15, 2005, 2397-2399 or Journal of Organic Chemistry, 66 (5), 2001, 1919-1923, etc.). It can be prepared by.
- Compound (54) can be prepared by changing the alcohol group of compound (53) to leaving group and reacting with p-methoxybenzylthiol (PMBSH) by making compound (21) of Scheme (3).
- PMBSH p-methoxybenzylthiol
- Compound (53) is reacted with 1-5 equivalents of triethylamine and 1-3 equivalents of MsCl in a 0 degree dichloromethane solvent to produce a sulfonate compound.
- Compound (54) can be prepared by adding a sulfonate compound to a PMBSNa solution prepared by adding 2-5 equivalents of NaH and 2-5 equivalents of PMBSH in a DMF solution.
- b is a reducing agent (eg, NaBH 4 ),
- c is thi-butylcarbonylchloride ( t BuCOCl), a base (eg, Et 3 N),
- R12 represents C 1 -C 6 -alkyl
- R14 represents p-MeOBn or Ph 3 C.
- Compound (17) is prepared by BOC protecting the amine group of compound (50), reducing the ester group with alcohol, protecting the alcohol group with an ester group, and finally deprotecting the BOC protecting group sequentially. Can be.
- the protection reaction of the amine group can proceed by the method shown in Scheme (9).
- Reduction of the ester group may be carried out by reacting with 2-5 equivalents of lithium borohydride for 1-5 hours in a tetrahydrofuran solvent at 0 degrees.
- the protecting reaction of the alcohol group may be carried out by reacting with t-BuCOCl for 10 minutes to 12 hours in the presence of 1 to 5 equivalents of a base such as triethylamine or pyridine in a dichloromethane solvent at 0 to 25 degrees.
- a base such as triethylamine or pyridine
- the deprotection reaction of the BOC group is dissolved in an inert solvent such as tetrahydrofuran, dioxane, ethyl acetate, dichloromethane, and 10 minutes to 12 equivalents with 1 to 10 equivalents of hydrochloric acid or acetic acid at a reaction temperature of 0 to 50 degrees.
- the reaction can proceed for a time.
- the compound of formula (1) obtained through the above method can be separated or purified from the reaction product by various methods such as recrystallization, iontophoresis, silica gel column chromatography or ion exchange resin chromatography.
- indole and indazole compounds according to the present invention can be synthesized by various methods.
- composition of the present invention containing the indole and indazole compounds of formula (1) as described above as active ingredients can be used for the preservation of cells or organs of animals. More specifically, the compositions of the present invention can be used to prevent damage due to cryopreservation of organs, independent cell systems or tissues, transplantation or reperfusion that occurs after transplantation.
- the effects of the compositions according to the invention are not limited to only those described above.
- a cell refers to an animal cell selected from the group consisting of hepatocytes, skin cells, mucosal cells, islet cells, neurons, chondrocytes, endothelial cells, epithelial cells, bone cells and muscle cells isolated from human or animal tissues. Or sperm, egg or fertilized egg of livestock and fish, wherein the organ is selected from the group consisting of organs of skin, cornea, kidney, heart, liver, pancreas, intestine, nerve, lung, placenta, umbilical cord or vascular system.
- the indole and indazole compounds according to the present invention can be used in addition to the existing long-term storage solution. Adding the indole and indazole compounds according to the present invention to a conventional organ preservation solution can greatly extend the shelf life of the organs mentioned above, and is effective because it can prevent or improve organ failure after organ transplantation.
- hepatocytes, pancreatic cells and the like of the animal can be preserved without freezing for a long time, thereby making it possible to use animal cells for cell engineering or tissue engineering to produce useful substances.
- a pharmaceutical composition according to the invention may comprise a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof, as necessary, together with the active ingredient.
- the pharmaceutical composition facilitates the administration of the compound into the organism.
- techniques for administering compounds including but not limited to oral, injection, aerosol, parenteral and topical administration, and the like.
- carrier refers to a substance that facilitates the addition of a compound into a cell or tissue.
- DMSO dimethylsulfoxide
- carrier commonly used to facilitate the incorporation of many organic compounds into cells or tissues of an organism.
- diluent is defined as a substance that not only stabilizes the biologically active form of a compound of interest, but also is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, which mimics the salt form of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
- pharmaceutically acceptable refers to a property that does not impair the biological activity and physical properties of the compound.
- the compounds of the present invention can be formulated in a variety of pharmaceutical dosage forms as desired.
- various pharmaceutically acceptable compounds may be selected depending on the active ingredient, in particular the compound of formula (1), a pharmaceutically acceptable salt or isomer thereof. Is mixed with a carrier.
- the pharmaceutical compositions according to the invention may be formulated as injectable preparations, oral preparations and the like as desired.
- the compounds of the present invention can be formulated in a known manner using known pharmaceutical carriers and excipients and incorporated into unit dose forms or in multidose containers.
- the form of the preparation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium and may contain conventional dispersing agents, suspending agents or stabilizers. In addition, for example, it may be in the form of a dry powder used by dissolving in sterile, pyrogen-free water before use.
- the compounds of the present invention may also be formulated in suppositories using conventional suppository bases such as cocoa butter or other glycerides.
- Solid dosage forms for oral administration may be capsules, tablets, pills, powders, and granules, and capsules and tablets are particularly useful.
- Tablets and pills are preferably prepared with enteric agents.
- Solid dosage forms can be prepared by mixing the compounds of the present invention with one or more inert diluents such as sucrose, lactose, starch and the like and with carriers such as lubricants, disintegrants, binders and the like, such as magnesium stearate.
- the compounds according to the invention or pharmaceutical compositions containing them are other active agents, for example, substances having a variety of different mechanisms of action, such as cryopreservation, transplantation or transplantation of organs, independent cell systems or tissues. It may be administered in combination with a substance which prevents damage due to reperfusion occurring.
- the amount of the compound of formula (1) depends on the prescription of the doctor depending on factors such as the patient's weight, age, the specific nature and severity of the disease. However, the amount used for organ transplantation in adults ranges from about 1 nM to 100 uM, and concentrations of about 10 uM or less will suffice, but for some patients higher dosages may be desirable.
- treatment means stopping or delaying the progression of the disease when used in a subject exhibiting symptoms of onset
- preventing means stopping or showing signs of development when used in a subject who is not at risk of developing the disease. Means to delay.
- M means molarity
- N means normal concentration
- Figure 1 shows the experimental results using the rat primary hepatocytes (primary hepatocyte) of the hepatocellular protective effect of the compound of Example 21 according to the present invention
- Figure 2 shows the recovery ability of the compounds of Examples 126, 127, 137, 138 according to the present invention in lung cell LB-HEL over time at 37 degrees after 24 hours cold-shock and the control drugs IM54 and nec-1 and Shown in comparison;
- Figure 3 shows the protective effect against cryopreservation damage of the Example 126 compound according to the present invention in the rat extraction perfusion model by comparing LDH, AST and ALT activity with HTK solution, which is an existing preservation solution;
- Figure 4 shows the protective effect against reperfusion damage after cryopreservation of the compound of Example 126 according to the present invention in a rat extraction perfusion model compared with the existing preservation solution HTK solution through LDH measurement;
- Figure 5 shows the protection effect against reperfusion damage after cryopreservation of the compound of Example 126 according to the present invention in the rat perfusion model by comparison with the HTK solution of the existing preservation solution through the measurement of the bile production capacity (Bile output).
- acetamide compound was dissolved in 200 ml of dichloromethane, and 13 ml (0.29 mol) of fuming nitric acid was added dropwise at 0 degree. Stirred at 0 ° C. to room temperature for 1 hour. Saturated aqueous sodium hydrogen carbonate solution was added and extracted with ethyl acetate. Washed with saturated sodium chloride solution and dried over anhydrous magnesium sulfate.
- the obtained nitrate compound was dissolved in 100 ml of methanol and 100 ml of tetrahydrofuran, and 6N-sodium hydride was added dropwise. Stir at room temperature for 6 hours. After completion of the reaction, the mixture was neutralized with 6N hydrochloric acid solution to pH 7 and extracted with ethyl acetate. Washed with saturated sodium chloride solution and dried over anhydrous magnesium sulfate to give 44 g (yield 83%) of the title compound.
- the obtained compound was dissolved using 100 ml of water, 100 ml of tetrahydrofuran and 100 ml of methanol. 103 g (1.84 mol) of iron powder and 99 g (1.84 mol) of ammonium chloride were added and stirred at 80 ° C. for 3 hours using a mechanical stirrer. After completion of the reaction, the mixture was filtered through celite, washed with methanol and concentrated. The resulting solid was filtered, washed with ether and dried to give 17 g (yield 36%) of 4- (pyridin-3-yloxy) -phenylamine.
- step 3 The compound obtained in step 3 was dissolved in 1000 ml of methanol, 7.1 g (31.1 mmol) of silver benzoate was added, and the mixture was sonicated for 1 hour using ultrasonic waves. After completion of the reaction, the reaction mixture was concentrated and separated by column chromatography. (R) -3-T-butoxycarbonylamino-4- (4-methoxy-benzylsulfanyl) -butyric acid methyl ester 35.2 g (95.3 mmol, yield 76% )
- the compound obtained in the step 2 was dissolved in 300 ml of tetrahydrofuran. 9.0 g (414.4 mmol) of lithium borohydride was added thereto, followed by stirring at 0 ° C. for 3 hours. After completion of the reaction, water was added and extracted with ethyl acetate. Washed with saturated sodium chloride solution and dried over anhydrous magnesium sulfate to obtain [(R) -2-hydroxy-1- (4-methoxy-benzylsulfanylmethyl) -ethyl] -carbamic acid thi-butyl ester.
- the alcohol compound obtained in the step 3 was dissolved in 300 ml of dichloromethane. 58 ml (414.4 mmol) of triethylamine and 28 ml (227.9 mmol) of trimethylacetyl chloride were added thereto, followed by stirring at 0 ° C. for 6 hours. After completion of the reaction, water was added and extracted with ethyl acetate. Washed with saturated sodium chloride solution and dried over anhydrous magnesium sulfate.
- Step 2 The compound obtained in Step 2 was dissolved in 10 ml of dichloroethane and 10 ml of toluene, and 1.29 g (3.2 mmol) of Laensone reagent was added. After refluxing for 4 hours, distillation under reduced pressure and water were added. The mixture was extracted with ethyl acetate, dried over anhydrous magnesium sulfate, filtered and the filtrate was distilled under reduced pressure. The concentrate was separated by column chromatography to obtain 100 mg (yield 22%) of compound 2- (4,5-dihydro-thiazol-2-yl) -7-nitro-1H-indole obtained as a result of the cyclization reaction.
- the thiazolin compound obtained in step 3 was dissolved in 50 ml of methanol. 10% Pd / C was added and stirred under hydrogen gas for 8 hours. After completion of the reaction, the mixture was filtered through celite and distilled under reduced pressure. Separation by column chromatography gave 80 mg (91%) of the title compound.
- Example 7 ⁇ (R) -2- [7- ( Tetrahydro -Pyran-4- Monoamino ) -1H-Indol-2-yl] -4,5-dihydro-thiazol-4-yl ⁇ -methanol
- the compound obtained in the step 1 was dissolved in 32 ml of methanol, 32 ml of tetrahydrofuran and 16 ml of water. 7 ml of 1N sodium hydroxide was added thereto and stirred at room temperature for 4 hours. After completion of the reaction, the mixture was distilled under reduced pressure and extracted with dichloromethane. Washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and the filtrate was filtered under reduced pressure. Purification by column chromatography gave 700 mg (yield 78%) of the title compound.
- Example 8 [(R) -2- (7- Cyclopentylamino -5- Fluoro -1H-indol-2-yl) -4,5- Dehydro -Thiazol-4-yl] -methanol
- step 1 The compound obtained in step 1 was dissolved in 200 ml of dichloromethane. Phosphorus pentachloride (17.1 g, 82 mmlol) was added and stirred at room temperature for 1 hour. After completion of the reaction, the resultant was concentrated, 200 ml of diethyl ether was added, the solid formed was filtered and dried to obtain [(R) -2- (5-chloro-7-nitro-1H-indol-2-yl) -4,5-dihydro- Thiazol-4-yl] -acetic acid methyl ester was obtained.
- Phosphorus pentachloride (17.1 g, 82 mmlol) was added and stirred at room temperature for 1 hour. After completion of the reaction, the resultant was concentrated, 200 ml of diethyl ether was added, the solid formed was filtered and dried to obtain [(R) -2- (5-chloro-7-nitro-1H-indol-2-yl) -4,5-di
- step 2 The compound obtained in step 2 was dissolved using 200 ml of tetrahydrofuran, 200 ml of methanol and 200 ml of water. 22.9 g (410 mmol) of iron powder and 21.9 g (410 mmol) of ammonium chloride were added and stirred at 60 ° C. for 1 hour using a mechanical stirrer. After completion of the reaction, 300 ml of tetrahydrofuran was added, filtered through Celite, and washed with 100 ml of tetrahydrofuran. After distillation under reduced pressure, the mixture was extracted using ethyl acetate. Washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and the filtrate was filtered under reduced pressure. Separation by column chromatography gave 9.0 g (yield 68%) of the title compound.
- Example 14 1- [4- (2- ⁇ (R) -2- [5- Chloro -7- ( Tetrahydro -Pyran-4- Monoamino ) -1H-indol-2-yl] -4,5- Dehydro -Thiazol-4-yl ⁇ -ethyl) -piperazin-1-yl] -2- Hydroxy - Ethanon synthesis
- step 1 The concentrated compound obtained in step 1 was dissolved in 10 ml of dichloromethane. 0.5 ml of 4N-hydrochloric acid solution was added dropwise and stirred at room temperature for 2 hours. After completion of the reaction, distillation under reduced pressure was concentrated. The concentrate was dissolved in 5 ml of N, N-dimethylformamide, glycolic acid (15.1 mg, 0.2 mmol), triethylamine (28 ul, 0.2 mmol), EDC (45 mg, 0.23 mmol) and HOBT (40 mg, 0.29). mmol) was added. Stir at room temperature for 8 hours. 1N hydrochloric acid solution was added and extracted with ethyl acetate. After drying over anhydrous magnesium sulfate, the filtrate was filtered under reduced pressure. Purification by column chromatography gave 5.1 mg (5% yield) of the title compound.
- Step 1 The compound obtained in Step 1 was dissolved in 300 ml of a mixed solution of water, tetrahydrofuran and methanol 1: 1: 1. 4.6 g (86.9 mmol) of ammonium chloride and 4.9 g (86.9 mmol) of iron were added and stirred at 60 ° C. for 30 minutes. Celite filter and distillation under reduced pressure. Saturated aqueous sodium bicarbonate solution was added to the concentrate and extracted with ethyl acetate. After drying over anhydrous magnesium sulfate, the filtrate was filtered under reduced pressure. Purification by column chromatography gave 400 mg (15%) of the title compound.
- Example 36 1- [4- (5- methyl -2-pyridin-2-yl-1H-indole-7- Monoamino ) -Piperidin-1-yl]- Ethanon synthesis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Materials For Medical Uses (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims (23)
- 하기 화학식 (1)의 화합물, 약제학적으로 허용되는 그의 염 또는 이성체를 유효성분으로 함유함을 특징으로 하는 세포 및 장기 보존제 조성물:[화학식 1]상기 식에서,X는 C 또는 N을 나타내고,n은 0 또는 1이며, X가 C일 때는 n이 1이고, X가 N일 때는 n이 0을 나타내며,A는 직접 결합을 나타내거나, C3-C8-사이클로알킬을 나타내거나, 페닐을 나타내거나, 각각 N, O 및 S 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 5~6원 헤테로아릴 또는 헤테로사이클을 나타내고,R1는 수소, -C(O)-B-X’-R7 또는 -(CR5R6)m-B-X’-R7를 나타내며,m은 0 내지 4이고,R5 및 R6는 각각 독립적으로 수소 또는 C1-C5-알킬을 나타내며,B는 직접 결합을 나타내거나, 임의로 옥소를 포함하는 C3-C8-사이클로알킬을 나타내거나, 각각 O, S 및 N 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 3~10원 헤테로사이클 또는 헤테로아릴을 나타내고,X’는 직접 결합을 나타내거나, -C(O)-, -SO2-, -CO2- 또는 -C(O)NR5-를 나타내며,R7은 수소, C1-C6-알킬, 할로게노-C1-C6-알킬, 할로겐, (CR5R6)m-페닐, (CR5R6)m-하이드록시 또는 (CR5R6)m-헤테로사이클을 나타내고, 여기에서 헤테로사이클은 임의로 옥소를 포함하며 N, O 및 S 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 3~10원환이며,R2는 -(CR5R6)m-D-X”-R8을 나타내고,D는 직접 결합을 나타내거나, 각각 임의로 옥소를 포함하며 임의로 융합되고 N, O 및 S 원자 중에서 선택된 1~4개의 헤테로 원자를 포함하는 3~10원 헤테로사이클 또는 헤테로아릴을 나타내며,X”는 직접 결합을 나타내거나, -C(O)-, -C(O)O-, -NR5C(O)-, -C(O)NR5- 또는 -O- 를 나타내고,R8은 수소, 할로겐, C1-C6-알킬, 할로게노-C1-C6-알킬, 트리(C1-C6-알킬)실란 또는 하이드록시-C1-C6-알킬을 나타내며,R3는 수소, 할로겐, 시아노, 니트로, 아릴-R9 또는 (CR5R6)m-D-R9를 나타내고,R9은 수소, 할로겐, C1-C6-알킬, 시아노, 니트로 또는 C1-C6-알콕시를 나타내며,R4는 -(CR5R6)m-Y-D-R10을 나타내고,Y는 직접 결합, -C(O)O- 또는 -O-를 나타내며,R10은 수소, 니트로, 할로겐, C1-C6-알킬, 카복시-C1-C6-알킬, 아릴 또는 -C(O)O-R5을 나타내고,상기에서, 알킬, 알콕시, 아릴, 사이클로알킬, 헤테로사이클 및 헤테로아릴은 임의로 치환될 수 있으며, 치환체는 하이드록시, 할로겐, 니트릴, 아미노, C1-C6-알킬아미노, 디(C1-C6-알킬)아미노, C1-C6-알킬, 할로게노-C1-C6-알킬, C1-C6-알킬설포닐, 아릴-C1-C6-알콕시 및 옥소로 이루어진 그룹에서 선택되는 하나 이상이다.
- 제1항에 있어서,X는 C 또는 N을 나타내고,n은 0 또는 1이며, X가 C일 때는 n이 1이고, X가 N일 때는 n이 0을 나타내며,A는 직접 결합을 나타내거나, 페닐을 나타내거나, 각각 N, O 및 S 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 5~6원 헤테로아릴 또는 헤테로사이클을 나타내고,R1는 수소, -C(O)-B-X’-R7 또는 -(CR5R6)m-B-X’-R7를 나타내며,m 은 0 내지 2이고,R5 및 R6는 각각 독립적으로 수소 또는 C1-C5-알킬을 나타내며,B는 직접 결합을 나타내거나, 임의로 옥소를 포함하는 C4-C7-사이클로알킬을 나타내거나, 각각 O, S 및 N 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 4~8원 헤테로사이클 또는 헤테로아릴을 나타내고,X’는 직접 결합을 나타내거나, -C(O)-, -SO2-, -CO2- 또는 -C(O)NH-를 나타내며,R7은 수소, C1-C6-알킬, 할로게노-C1-C6-알킬, 할로겐, (CR5R6)m-페닐, (CR5R6)m-하이드록시, (CR5R6)m-헤테로사이클을 나타내고, 여기에서 헤테로사이클은 임의로 옥소를 포함하며 N, O 및 S 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 4~8원환이며,R2는 -(CR5R6)m-D-X”-R8을 나타내고,D는 직접 결합을 나타내거나, 각각 임의로 옥소를 포함하며 임의로 융합되고 N, O 및 S 원자 중에서 선택된 1~4개의 헤테로 원자를 포함하는 4~8원 헤테로사이클 또는 헤테로아릴을 나타내며,X”는 -C(O)-, -C(O)O-, -NR5C(O)-, -C(O)NR5- 또는 -O- 를 나타내고,R8은 수소, 할로겐, C1-C6-알킬, 할로게노-C1-C6-알킬, 트리(C1-C6-알킬)실란 또는 하이드록시-C1-C6-알킬을 나타내며,R3는 수소, 할로겐, 시아노, 니트로, 아릴-R9 또는 (CR5R6)m-D-R9를 나타내고,R9은 수소, 할로겐, C1-C6-알킬, 시아노, 니트로 또는 C1-C6-알콕시를 나타내며,R4는 -(CR5R6)m-Y-D-R10을 나타내고,Y는 직접 결합, -C(O)O- 또는 -O-를 나타내며,R10은 수소, 니트로, 할로겐, C1-C6-알킬, 카복시-C1-C6-알킬, 아릴 또는 -C(O)O-R5를 나타내는 조성물.
- 제2항에 있어서, A가 페닐, 피리딘, 1,4-피라진, 4,5-디하이드로-티아졸, 티아졸, 4,5-디하이드로옥사졸, [1,2,4]옥사디아졸 및 [1,3,4]옥사디아졸로 이루어진 그룹에서 선택되는 조성물.
- 제2항에 있어서, R1이 -C(O)-B-X’-R7 또는 -(CHR5)m-B-X’-R7을 나타내고, 여기에서 m은 0 내지 2의 수이며, R5는 C1-C3-알킬을 나타내고, B는 직접 결합을 나타내거나, 임의로 옥소를 포함하는 C5-C6-사이클로알킬을 나타내거나, 각각 O, S 및 N 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 5~6원 헤테로사이클 또는 헤테로아릴을 나타내고, X’는 직접 결합을 나타내거나, -C(O)-, -SO2-, -CO2- 또는 -C(O)NH- 를 나타내며, R7은 수소, C1-C3-알킬, 할로게노-C1-C3-알킬, 할로겐, (CH2)m-페닐, (CH2)m-하이드록시, (CH2)m-헤테로사이클을 나타내며, 여기에서 헤테로사이클은 임의로 옥소를 포함하고, N, O 및 S 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 5~6원환인 조성물.
- 제5항에 있어서, B가 사이클로펜틸, 사이클로헥실, 피페리딘, 테트라하이드로피란, 옥소사이클로헥실, 피롤리딘, 디플루오로사이클로헥실 및 테트라하이드로퓨란으로 이루어진 그룹에서 선택되는 조성물.
- 제5항에 있어서, R7이 수소, 메틸, 에틸, 이소프로필, 벤질, 하이드록시메틸, (몰포린-4-일)-에틸, 테트라하이드로퓨란, 2,2,2-트리플루오로에틸, 하이드록시에틸, 1,1-디옥소티오몰포린, 테트라하이드로피란, (테트라하이드로피란-4-일)-메틸 및 트리플루오로메틸로 이루어진 그룹에서 선택되는 조성물.
- 제2항에 있어서, D는 직접 결합을 나타내거나, 피페라진, 피롤리딘, 몰포린, 1,1-디옥소티오몰포린 및 옥소피페라진으로 이루어진 그룹에서 선택되는 조성물.
- 제2항에 있어서, R8이 수소, 에틸, 하이드록시메틸, 메틸 및 불소로 이루어진 그룹에서 선택되는 조성물.
- 제2항에 있어서, R3가 수소 또는 할로겐을 나타내거나, 알콕시에 의해 임의로 치환된 페닐을 나타내거나, 환 멤버로서 N, S 및 O 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하며 임의로 옥소를 포함하는 6원 헤테로사이클릴메틸을 나타내는 조성물.
- 제10항에 있어서, R3가 수소, 브롬, 페닐, 메톡시-페닐, 몰포린-4-일-메틸, 옥소피페라진-4-일-메틸, 1,1-디옥소-티오몰포린-4-일-메틸로 이루어진 그룹에서 선택되는 조성물.
- 제2항에 있어서, R4가 -(CH2)m-Y-D-R10을 나타내고, 여기에서 m은 0 내지 2이며, Y는 직접 결합을 나타내거나 -C(O)O- 또는 -O-를 나타내고, D는 피리딘을 나타내거나 임의로 옥소를 포함하며 N, S 및 O 원자 중에서 선택된 1~3개의 헤테로 원자를 포함하는 5~6원 헤테로사이클을 나타내며, R10은 수소, 할로겐, C1-C3-알킬, -(CH2)-CO2H, 아릴 또는 -C(O)O-R5을 나타내는 조성물.
- 제12항에 있어서, D가 1,1-디옥소-티오-몰포린, 옥소피페라진, 피리딘, 몰포린 및 4,5-디하이드로-티아졸로 이루어진 그룹에서 선택되는 조성물.
- 제12항에 있어서, R10이 수소, 불소, 염소, 브롬, 메틸, 에틸 및 -(CH2)-CO2H 로 이루어진 그룹에서 선택되는 조성물.
- 제2항에 있어서,사이클로펜틸-[2-(4,5-디하이드로-1,3-티아졸-2-일)-1H-인돌-7-일]-아민;[2-(4,5-디하이드로-티아졸-2-일)-1H-인돌-7-일]-(4-메틸-사이클로헥실)-아민;[2-(4,5-디하이드로-티아졸-2-일)-1H-인돌-7-일]-피페리딘-4-일-아민;2-5-[7-(테트라하이드로-피란-4-일아미노)-1H-인돌-2-일]-[1,2,4]옥사디아졸-3-일}-에탄올;[(R)-2-(7-사이클로펜틸아미노-1H-인돌-2-일)-4,5-디하이드로-1,3-티아졸-4-일]-메탄올;사이클로펜틸-[2-((R)-4-피롤리딘-1-일메틸-4,5-디하이드로-티아졸-2-일)-1H-인돌-7-일]-아민;{(R)-2-[7-(테트라하이드로-피란-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-티아졸-4-일}-메탄올;[(R)-2-(7-사이클로펜틸아미노-5-플루오로-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-메탄올;{(R)-2-[5-플루오로-7-(테트라하이드로-피란-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-티아졸-4-일}-메탄올;{(R)-2-[5-(피리딘-3-일옥시)-7-(테트라하이드로-피란-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-티아졸-4-일}-메탄올;[(R)-2-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-아세트산;[(R)-2-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-아세트산 에틸 에스터;2-{(R)-2-[5-클로로-7-(테트라하이드로-피란-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-티아졸-4-일}-에탄올;1-[4-(2-{(R)-2-[5-클로로-7-(테트라하이드로-피란-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-티아졸-4-일}-에틸)-피페라진-1-일]-2-하이드록시-에타논;1-(2-{(R)-2-[5-클로로-7-(테트라하이드로-피란-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-티아졸-4-일}-에틸)-피롤리딘-3-올;[(R)-2-(5-브로모-7-사이클로펜틸아미노-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-아세트산;[(R)-2-(7-사이클로펜틸아미노-5-에톡시-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-아세트산;[(R)-2-(7-사이클로펜틸아미노-5-에톡시-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-아세트산;[2-(7-사이클로펜틸아미노-5-페녹시-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-아세트산;[(R)-2-(7-사이클로펜틸아미노-5-페녹시-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-아세트산;[(S)-2-(7-사이클로펜틸아미노-5-페녹시-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-아세트산;3-[(R)-2-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-프로피온산 에틸 에스터;3-[(R)-2-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-4,5-디하이드로-티아졸-4-일]-프로피온산;사이클로펜틸-(2-피리딘-2-일-1H-인돌-7-일)-아민;사이클로펜틸-(2-피라진-2-일-1H-인돌-7-일)아민;(2-피라진-2-일-1H-인돌-7-일)-(테트라하이드로피란-4-일)-아민;사이클로펜틸-(2-티아졸-2-일-1H-인돌-7-일)-아민;2-(7-사이클로펜틸아미노-5-메틸-1H-인돌-2-일)-티아졸-4-카르복실산 에틸 에스터;2-(7-사이클로펜틸아미노-5-메틸-1H-인돌-2-일)-티아졸-4-카르복실산;[2-(7-사이클로펜틸아미노-5-메틸-1H-인돌-2-일)-티아졸-4-일]-메탄올;[2-(7-사이클로펜틸아미노-5-메틸-1H-인돌-2-일)-티아졸-5-일]-메탄올;사이클로펜틸-(5-메틸-2-[1,3,4]옥사디아졸-2-일-1H-인돌-7-일)-아민;사이클로펜틸-(5-메틸-2-피리딘-2-일-1H-인돌-7-일)-아민;(5-메틸-2-피리딘-2-일-1H-인돌-7-일)-(테트라하이드로-피란-4-일)-아민;사이클로헥실-(5-메틸-2-피리딘-2-일-1H-인돌-7-일)-아민;1-[4-(5-메틸-2-피리딘-2-일-1H-인돌-7-일아미노)-피페리딘-1-일]-에타논;(1-메틸-피페리딘-4-일)-(5-메틸-2-피리딘-2-일-1H-인돌-7-일)-아민;4-(5-메틸-2-피리딘-2-일-1H-인돌-7-일아미노)-사이클로헥사논;(1-벤질-피롤리딘-3-일)-(5-메틸-2-피리딘-2-일-1H-인돌-7-일)-아민;사이클로펜틸메틸-(5-메틸-2-피리딘-2-일-1H-인돌-7-일)-아민;N-(5-메틸-2-피리딘-2-일-1H-인돌-7-일)-벤자미드;사이클로펜틸-(5-메틸-2-피라진-2-일-1H-인돌-7-일)-아민;사이클로펜틸-(5-에톡시-2-피리딘-2-일-1H-인돌-7-일)-아민;사이클로펜틸-(5-페녹시-2-피리딘-2-일-1H-인돌-7-일)-아민;사이클로펜틸-(3,5-디메틸-2-페닐-1H-인돌-7-일)-아민;사이클로펜틸-(5-메틸-2-페닐-1H-인돌-7-일)-아민;(2-사이클로헥실-5-메틸-1H-인돌-7-일)-사이클로펜틸-아민;사이클로펜틸-[5-메틸-2-(6-메틸-피리딘-2-일)-1H-인돌-7-일]-아민;(5-메틸-2-페닐-1H-인돌-7-일)-(테트라하이드로-피란-4-일)-아민;(5-메틸-2-페닐-1H-인돌-7-일)-(1-메틸-피페리딘-4-일)-아민;1-[4-(5-메틸-2-페닐-1H-인돌-7-일아미노)-피페리딘-1-일]-에타논;(5-메틸-2-페닐-1H-인돌-7-일)-피페리딘-4-일-아민 하이드로클로라이드;2-하이드록시-1-[4-(5-메틸-2-페닐-1H-인돌-7-일아미노)-피페리딘-1-일]-에타논;(1-메탄설포닐-피페리딘-4-일)-(5-메틸-2-페닐-1H-인돌-7-일)-아민;4-(5-메틸-2-페닐-1H-인돌-7-일아미노)-사이클로헥산카르복실산;4-(5-메틸-2-페닐-1H-인돌-7-일아미노)-사이클로헥산카르복실산 (2-몰포린-4-일-에틸)-아마이드;사이클로펜틸메틸-(5-메틸-2-페닐-1H-인돌-7-일)-아민;(5-메틸-2-페닐-1H-인돌-7-일)-(테트라하이드로-피란-4-일메틸)-아민;(5-클로로-2-페닐-1H-인돌-7-일)-사이클로펜틸-아민;(5-클로로-2-페닐-1H-인돌-7-일)-(테트라하이드로-피란-4-일)-아민;(5-클로로-2-페닐-1H-인돌-7-일)-(1-메틸-피페리딘-4-일)-아민;(5-클로로-2-페닐-1H-인돌-7-일)-사이클로헥실-아민;(1-벤질-피롤리딘-3-일)-(5-클로로-2-페닐-1H-인돌-7-일)-아민;4-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-벤조산 메틸 에스터;4-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-벤조산;[4-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-페닐]-메탄올;4-(7-사이클로펜틸아미노-5-메틸-1H-인돌-2-일)-벤조산 메틸 에스터;2-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-벤조산 메틸 에스터;2-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-벤조산;[2-(5-클로로-7-사이클로펜틸아미노-1H-인돌-2-일)-페닐]-메탄올;7-사이클로펜틸아미노-2-페닐-1H-인돌-5-카르복실산 에틸에스터;7-사이클로펜틸아미노-2-페닐-1H-인돌-5-카르복실산;(7-사이클로펜틸아미노-2-페닐-1H-인돌-5-일)-메탄올;(7-사이클로펜틸아미노-2-페닐-1H-인돌-5-일)-아세트산 에틸 에스터;(7-사이클로펜틸아미노-2-페닐-1H-인돌-5-일)-아세트산;2-[(4S)-2-[5-메틸-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[5-클로로-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[7-[(4,4-디플루오로사이클로헥실)아미노]-5-메틸-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[7-(옥산-4-일아미노)-5-페녹시-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4R)-2-[7-(옥산-4-일아미노)-5-페녹시-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4R)-2-[7-(옥산-4-일메틸아미노)-5-페녹시-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[7-(사이클로펜틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[7-[(1-아세틸피롤리딘-3-일)아미노]-5-메틸-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[7-(옥산-4-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[7-(옥산-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[7-(옥산-2-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[5-메틸-7-[[1-(3,3,3-트리플루오로프로파노일)피페리딘-4-일]아미노]-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4R)-2-[7-(사이클로펜틸아미노)-5-메틸-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4R)-2-[5-메틸-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;4-[2-[(4S)-2-[5-메틸-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]에틸]피페라진-2-온;2-[(4S)-4-[2-(1,1-디옥소-1,4-시아지난-4-일)에틸]-4,5-디하이드로-1,3-티아졸-2-일]-5-메틸-N-(옥산-4-일메틸)-1H-인돌-7-일-아민;N-(4,4-디플루오로사이클로헥실)-5-메틸-2-[(4S)-4-(2-몰포린-4-일에틸)- 4,5-디하이드로-1,3-티아졸-2-일]-1H-인돌-7-일-아민;4-[2-[(4S)-2-[7-[(4,4-디플루오로사이클로헥실)아미노]-5-메틸-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]에틸]피페라진-2-온;4-[2-[(4S)-2-[7-(옥산-4-일메틸아미노)-5-페녹시-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]에틸]피페라진-2-온;2-[(4S)-4-(2-몰포린-4-일에틸)-4,5-디하이드로-1,3-티아졸-2-일]-N-(옥산-4-일메틸)-5-페녹시-1H-인돌-7-아민;5-메틸-2-[(4S)-4-(2-몰포린-4-일에틸)-4,5-디하이드로-1,3-티아졸-2-일]-N-(옥산-4-일메틸)-1H-인돌-7-아민;1-[2-[(4S)-2-[5-메틸-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]에틸]피페리딘-4-카복시아미드;[(2R)-1-[2-[(4S)-2-[5-메틸-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]에틸]피롤리딘-2-일]메탄올;(2S)-1-[2-[(4S)-2-[5-메틸-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]에틸]피롤리딘-2-카복시아미드;4-[2-[(4R)-2-[7-(사이클로펜틸아미노)-5-메틸-1H-인돌-2-일]-4,5-디하이드로-1,3-티아졸-4-일]에틸]피페라진-2-온;2-[(4S)-2-[7-(사이클로펜틸아미노)-5-메틸-1H-인돌-2-일]-4,5-디하이드로-1,3-옥사졸-4-일]아세트산;{(S)-2-[5-메틸-7-(테트라하이드로피란-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-옥사졸-4-일}-아세트산;2-[(4S)-2-[5-메틸-7-(테트라하이드로피란-4-일아미노)-1H-인돌-2-일]-4,5-디하이드로-1,3-옥사졸-4-일]에탄올;{5-메틸-2-[(S)-4-(2-몰포린-4-일-에틸)-4,5-디하이드로-1,3-옥사졸-2-일]-1H-인돌-7-일}-(테트라하이드로-피란-4-일)아민4-[(5-클로로-2-페닐-1H-인돌-7-일)아미노]-N-에틸피페리딘-1-카복시아미드;[4-[(5-클로로-2-페닐-1H-인돌-7-일)아미노]피페리딘-1-일]-(옥소란-3-일)메탄온;2-[7-(옥산-4-일아미노)-2-페닐-1H-인돌-5-일]아세트산;2-[7-(사이클로펜틸메틸아미노)-2-페닐-1H-인돌-5-일]아세트산;5-플루오로-N-(1-메틸피페리딘-4-일)-2-페닐-1H-인돌-7-아민;2-[4-[(5-플루오로-2-페닐-1H-인돌-7-일)아미노]피페리딘-1-일]에탄온;5-플루오로-N-[1-(옥산-4-일)피페리딘-4-일]-2-페닐-1H-인돌-7-아민;N-[1-(1,1-디옥시안-4-일)피페리딘-4-일]-5-플루오로-2-페닐-1H-인돌-7-아민;N-(옥산-4-일)-5-페녹시-2-페닐-1H-인돌-7-아민;메틸 2-[(5-플루오로-2-페닐-1H-인돌-7-일)아미노]아세테이트;2-[(5-플루오로-2-페닐-1H-인돌-7-일)아미노]아세트산;메틸 2-[(5-클로로-2-페닐-1H-인돌-7-일)아미노]프로파노에이트;2-[(5-클로로-2-페닐-1H-인돌-7-일)아미노]프로파노산;2-[(5-페녹시-2-페닐-1H-인돌-7-일)아미노]아세트산;2-[(5-페녹시-2-페닐-1H-인돌-7-일)아미노]프로파노산;2-[(4S)-2-[7-(옥산-4-일메틸아미노)-2-페닐-1H-인돌-5-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;2-[(4S)-2-[7-(사이클로펜틸아미노)-2-페닐-1H-인돌-5-일]-4,5-디하이드로-1,3-티아졸-4-일]아세트산;메틸 2-[4-[5-클로로-7-(옥산-4-일아미노)-1H-인돌-2-일]페닐]아세테이트;메틸 2-[4-[5-클로로-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]페닐]아세테이트;2-[4-[5-클로로-7-(옥산-4-일아미노)-1H-인돌-2-일]페닐]아세트산;5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-N-(옥산-4-일)-2-페닐-1H-인돌-7-아민;5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-N-(옥산-4-일메틸)-2-페닐-1H-인돌-7-아민;4-[[7-(옥산-4-일아미노)-2-페닐-1H-인돌-5-일]메틸]피페라진-2-온;5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-2-페닐-N-피페리딘-4-일-1H-인돌-7-아민;[4-[[5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-2-페닐-1H-인돌-7-일]아미노]피페리딘-1-일]-(옥소란-3-일)메탄온;N-[4-[5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-7-(옥산-4-일아미노)-1H-인돌-2-일]페닐]아세트아미드;N-[4-[7-(디사이클로펜틸아미노)-5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-1H-인돌-2-일]페닐]아세트아미드;N-[4-[5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-7-(옥산-4-일메틸아미노)-1H-인돌-2-일]페닐]아세트아미드;N-사이클로펜틸-5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-2-(4-메톡시페닐)-1H-인돌-7-아민;5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-2-(4-메톡시페닐)-N-(옥산-4-일)-1H-인돌-7-아민;5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-N-(3-메톡시부틸)-2-페닐-1H-인돌-7-아민;5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-2-(3-플루오로페닐)-N-(옥산-4-일)-1H-인돌-7-아민;N-사이클로펜틸-5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-2-(3-플루오로페닐)-1H-인돌-7-아민;3-브로모-5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-N-(옥산-4-일)-2-페닐-1H-인돌-7-아민;3-브로모-5-(몰포린-4-일메틸)-N-(옥산-4-일)-2-페닐-1H-인돌-7-아민;3-브로모-N-사이클로펜틸-5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-2-페닐-1H-인돌-7-아민;3-브로모-5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-N-(옥산-4-일)-2-페닐-1H-인돌-7-아민;5-클로로-N-(옥산-4-일)-3-페닐-1H-인돌-7-아민;5-클로로-N-사이클로펜틸-3-페닐-1H-인돌-7-아민;5-클로로-N-(옥산-4-일메틸)-3-페닐-1H-인돌-7-아민;5-[(1,1-디옥소-1,4-시아지난-4-일)메틸]-N-(옥산-4-일)-3-페닐-2-트리메틸실릴-1H-인돌-7-아민;4-[[5-클로로-7-(사이클로펜틸아미노)-2-페닐-1H-인돌-3-일]메틸]피페라진-2-온;4-[[5-클로로-7-(옥산-4-일아미노)-2-페닐-1H-인돌-3-일]메틸]피페라진-2-온;4-[[5-클로로-7-(옥산-4-일메틸아미노)-2-페닐-1H-인돌-3-일]메틸]피페라진-2-온;N-사이클로펜틸-3-(4-메톡시페닐)-1H-인다졸-7-아민;3-(4-메톡시페닐)-N-(옥산-4-일)-1H-인다졸-7-아민;3-(4-메톡시페닐)-N-(옥산-4-일메틸)-1H-인다졸-7-아민; 및2-(7-사이클로펜틸아미노-2-페닐-1H-인돌-5-일)-에탄올으로 구성된 그룹에서 선택되는 화합물인 조성물.
- 제1항에 있어서, 화학식 (1) 화합물의 약제학적으로 허용되는 염 또는 이성체를 활성 성분으로 함유함을 특징으로 하는 세포, 조직 및 장기 보존제 조성물.
- 제1항에 있어서, 세포가 사람 또는 동물의 조직 또는 장기로부터 단리한 간세포, 피부세포, 점막세포, 랑게르한스섬 세포, 신경세포, 연골세포, 내피세포, 상피세포, 골세포 및 근육세포로 구성된 그룹으로부터 선택된 동물세포, 또는 가축 및 어류의 정자, 알 또는 수정란인 조성물.
- 제1항에 있어서, 장기가 피부, 각막, 신장, 심장, 간장, 췌장, 장, 신경, 폐, 태반, 탯줄 및 혈관으로 구성된 그룹으로부터 선택되는 조성물.
- 제1항에 있어서, 조직이 피부, 각막, 신장, 심장, 간장, 췌장, 장, 신경, 폐, 태반, 탯줄 및 혈관으로 구성된 그룹으로부터 선택되는 조성물.
- 제 1 항에 있어서, 기관, 독립된 세포시스템 또는 조직의 저온보관, 이식수술 또는 이식 후 발생하는 재관류에 의한 손상을 예방하기 위한 조성물.
- 제1항에 따른 조성물을 이식용으로 사용되는 동물의 세포, 조직 또는 장기의 보존에 사용하는 방법.
- 활성 성분으로서 제1항에 따른 화학식 (1)의 화합물, 약제학적으로 허용되는 그의 염 또는 이성체를 약제학적으로 허용되는 담체와 함께 혼합하는 단계를 포함함을 특징으로 하여 동물의 세포, 조직 또는 장기 보존제 조성물을 제조하는 방법.
- 인공 장기를 제작함에 있어 제20항에 따른 조성물을 세포, 조직 또는 장기를 배양 및 보존하는데 사용하는 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/811,525 US20100291533A1 (en) | 2008-01-04 | 2009-01-05 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect |
JP2010541405A JP5188583B2 (ja) | 2008-01-04 | 2009-01-05 | 細胞、組織及び臓器保存効果を有するインドール及びインダゾール誘導体 |
CN200980104944.0A CN101952281B (zh) | 2008-01-04 | 2009-01-05 | 具有细胞、组织及器官保存效果的吲哚及吲唑衍生物 |
EP09700417.0A EP2230238B1 (en) | 2008-01-04 | 2009-01-05 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect |
BRPI0906612-8A BRPI0906612A2 (pt) | 2008-01-04 | 2009-01-05 | Composição para preservar células, tecidos e órgãos, e, métodos para usar a composição e de preparação de uima composição |
US13/534,682 US8349885B2 (en) | 2008-01-04 | 2012-06-27 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20080001477 | 2008-01-04 | ||
KR10-2008-0001477 | 2008-01-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/811,525 A-371-Of-International US20100291533A1 (en) | 2008-01-04 | 2009-01-05 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect |
US13/534,682 Division US8349885B2 (en) | 2008-01-04 | 2012-06-27 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2009088192A2 true WO2009088192A2 (ko) | 2009-07-16 |
WO2009088192A3 WO2009088192A3 (ko) | 2009-10-01 |
WO2009088192A9 WO2009088192A9 (ko) | 2009-11-19 |
Family
ID=40853579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/000031 WO2009088192A2 (ko) | 2008-01-04 | 2009-01-05 | 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20100291533A1 (ko) |
EP (1) | EP2230238B1 (ko) |
JP (1) | JP5188583B2 (ko) |
KR (1) | KR101098583B1 (ko) |
CN (1) | CN101952281B (ko) |
BR (1) | BRPI0906612A2 (ko) |
RU (1) | RU2460525C2 (ko) |
WO (1) | WO2009088192A2 (ko) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010536846A (ja) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 |
WO2011052950A3 (en) * | 2009-10-26 | 2011-11-24 | Lg Life Sciences Ltd. | Pharmaceutical composition comprising indole compound |
WO2015100312A1 (en) * | 2013-12-24 | 2015-07-02 | Virginia Commonwealth University | Uses of oxygenated cholesterol sulfates (ocs) |
US9480692B2 (en) | 2011-04-06 | 2016-11-01 | Virginia Commonwealth University | Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
EP3107919A4 (en) * | 2014-02-20 | 2017-11-22 | University of Florida Research Foundation | Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment |
US10144759B2 (en) | 2004-10-25 | 2018-12-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
US11406646B2 (en) | 2016-08-02 | 2022-08-09 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
WO2022220517A1 (ko) * | 2021-04-12 | 2022-10-20 | 주식회사 미토이뮨테라퓨틱스 | 줄기세포의 염증 또는 노화 억제용 조성물 및 이의 염증 또는 노화 억제 방법 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009082152A2 (en) | 2007-12-20 | 2009-07-02 | Lg Life Sciences Ltd. | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient |
KR20110002472A (ko) * | 2008-04-10 | 2011-01-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 고리 화합물 및 이의 용도 |
KR101404151B1 (ko) * | 2011-11-25 | 2014-06-05 | 가톨릭대학교 산학협력단 | 안과 질환의 예방 및 치료용 약학 조성물 |
KR101377478B1 (ko) * | 2012-05-10 | 2014-03-26 | 부산대학교 산학협력단 | 골량 저하 관련 질환의 예방 또는 치료용 약학 조성물 및 건강기능식품 |
KR20140129221A (ko) * | 2012-05-21 | 2014-11-06 | 에스알씨, 인코퍼레이트 | 리신과 기타 리보솜 비활성화 단백질의 검출을 위한 방법과 시스템 |
KR101941004B1 (ko) * | 2013-03-25 | 2019-01-23 | 주식회사 엘지화학 | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 |
CN105636956B (zh) * | 2013-08-22 | 2019-07-09 | 株式会社Lg化学 | 作为细胞坏死阻碍剂的吲哚化合物 |
EP3037412B1 (en) * | 2013-08-22 | 2020-09-30 | LG Chem, Ltd. | Indole amide compound as inhibitor of necrosis |
WO2015111947A1 (en) * | 2014-01-24 | 2015-07-30 | Lg Life Sciences Ltd. | Composition for preventing or treating acute lung injury and acute respiratory distress syndrome |
CN106659722A (zh) * | 2014-04-18 | 2017-05-10 | 株式会社Lg生命科学 | 用于预防或治疗脂肪肝疾病的组合物 |
CN104098498A (zh) * | 2014-07-30 | 2014-10-15 | 天津市斯芬克司药物研发有限公司 | 一种吲唑类化合物及其制备方法 |
WO2016154452A2 (en) | 2015-03-24 | 2016-09-29 | Osiris Therapeutics, Inc. | Compositions comprising meniscal tissues and uses thereof |
CA3044746A1 (en) * | 2016-11-24 | 2018-05-31 | Sigmadrugs Kutato Korlatolt Felelossegu Tarsasag | Compositions for organ preservation |
CN114080383B (zh) * | 2019-06-19 | 2024-07-23 | 株式会社Lg化学 | 制备吲哚或吲唑化合物的方法 |
WO2020256437A1 (ko) * | 2019-06-19 | 2020-12-24 | 주식회사 엘지화학 | 인돌 또는 인다졸 화합물의 제조방법 |
EP3971185B1 (en) * | 2019-06-19 | 2024-04-17 | LG Chem, Ltd. | Method for preparing indole or indazole compound |
CN114080382B (zh) * | 2019-06-19 | 2024-05-24 | 株式会社Lg化学 | 制备吲哚或吲唑化合物的方法 |
CN110790923A (zh) * | 2019-10-12 | 2020-02-14 | 天津大学 | 一种γ-聚谷氨酸-接枝-吲哚结构伯胺及制备方法和应用 |
CN115361866A (zh) * | 2020-03-31 | 2022-11-18 | 株式会社Lg化学 | 用于保护胰岛移植的组合物 |
US20240043409A1 (en) | 2021-04-12 | 2024-02-08 | Mitoimmune Therapeutics Inc. | Crystalline forms of 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-n-(tetrahydro-2h-pyran-4-yl)-1h-indol-7-amine |
KR20220141252A (ko) | 2021-04-12 | 2022-10-19 | 주식회사 미토이뮨테라퓨틱스 | 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민 황산염 및 이의 신규 결정형 |
CN113406051B (zh) * | 2021-06-17 | 2022-07-05 | 中国农业科学院农业质量标准与检测技术研究所 | 一种联合筛查鱼上皮细胞早期损伤的高通量分析方法 |
KR20230020360A (ko) * | 2021-08-02 | 2023-02-10 | 주식회사 미토이뮨테라퓨틱스 | 신규한 인돌 유도체, 이를 포함하는 약학적 조성물, 및 이의 용도 |
EP4382524A1 (en) * | 2021-08-02 | 2024-06-12 | MitoImmune Therapeutics Inc. | Indole derivative, method for preparing same, and use thereof |
WO2024158205A1 (ko) * | 2023-01-25 | 2024-08-02 | 주식회사 미토이뮨테라퓨틱스 | 치환기를 가지는 인돌 유도체, 및 약학적 용도 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007276A1 (fr) | 1993-09-10 | 1995-03-16 | Eisai Co., Ltd. | Derives bicycliques heterocycliques d'ester sulfonique et de sulfonamide |
WO1999002501A1 (en) | 1997-07-09 | 1999-01-21 | Astra Pharmaceuticals Ltd. | Novel compounds |
JP2001233855A (ja) | 2000-02-25 | 2001-08-28 | Basf Ag | インドールタイプの化合物の製造方法 |
US20040019215A1 (en) | 2002-03-19 | 2004-01-29 | Kolb Hartmuth C. | Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates |
WO2004018428A1 (en) | 2002-08-23 | 2004-03-04 | Pharmacia & Upjohn Company Llc | Antibacterial benzoic acid derivatives |
WO2006016079A2 (fr) | 2004-07-13 | 2006-02-16 | Vichem | Procede perfectionne de fabrication d'acide phosphorique |
WO2006112549A1 (ja) | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
WO2007040289A1 (en) | 2005-10-05 | 2007-04-12 | Promeditech Inc. | Deformylase inhibitor, process for the preparation thereof, and composition comprising the same |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE792078A (fr) * | 1971-12-01 | 1973-05-29 | Wander Ag Dr A | Nouveaux derives de l'indazole, leur preparation et leur application comme medicaments |
DE2653005A1 (de) * | 1975-12-03 | 1977-06-08 | Sandoz Ag | Neue organische verbindungen, ihre verwendung und herstellung |
JPS6160648A (ja) * | 1984-08-31 | 1986-03-28 | Teikoku Hormone Mfg Co Ltd | 2−(3,5−ジアルキル−4−ヒドロキシフエニル)インド−ル誘導体 |
US5177088A (en) * | 1991-04-17 | 1993-01-05 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted 3-(pyridinylamino)-indoles |
SE9302431D0 (sv) * | 1993-07-16 | 1993-07-16 | Ab Astra | Use of indenoindole compounds |
EP0950405A4 (en) * | 1996-06-26 | 2004-03-17 | Chugai Pharmaceutical Co Ltd | TREATMENT OF KIDNEY DISEASES AND PROTECTION OF THE ORGANS |
EP1057484A4 (en) * | 1998-02-23 | 2002-11-20 | Sagami Chem Res | INHIBITORS OF CELL DEATH |
JP5230042B2 (ja) * | 1999-06-02 | 2013-07-10 | 株式会社ビーエムジー | 動物の細胞または臓器の保存剤およびその保存方法。 |
EP1208748A4 (en) * | 1999-08-31 | 2002-11-20 | Fujisawa Pharmaceutical Co | PRESERVATIVES FOR ORGANS |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US7696202B2 (en) * | 2004-11-10 | 2010-04-13 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
EP1828169A2 (en) * | 2004-12-07 | 2007-09-05 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
MX2009003972A (es) * | 2006-10-19 | 2009-04-27 | Takeda Pharmaceutical | Compuesto de indol. |
JP2008208086A (ja) * | 2007-02-27 | 2008-09-11 | Institute Of Physical & Chemical Research | 3−アミノ−2−インドリルブチロラクタム誘導体、その製造法、及びこれを有効成分とする医薬 |
EP2178870B1 (en) * | 2007-08-17 | 2018-09-19 | LG Chem, Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
WO2009082152A2 (en) * | 2007-12-20 | 2009-07-02 | Lg Life Sciences Ltd. | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient |
-
2009
- 2009-01-05 US US12/811,525 patent/US20100291533A1/en not_active Abandoned
- 2009-01-05 JP JP2010541405A patent/JP5188583B2/ja active Active
- 2009-01-05 WO PCT/KR2009/000031 patent/WO2009088192A2/ko active Application Filing
- 2009-01-05 KR KR1020090000363A patent/KR101098583B1/ko active IP Right Grant
- 2009-01-05 RU RU2010132644/15A patent/RU2460525C2/ru active
- 2009-01-05 EP EP09700417.0A patent/EP2230238B1/en active Active
- 2009-01-05 BR BRPI0906612-8A patent/BRPI0906612A2/pt not_active Application Discontinuation
- 2009-01-05 CN CN200980104944.0A patent/CN101952281B/zh active Active
-
2012
- 2012-06-27 US US13/534,682 patent/US8349885B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007276A1 (fr) | 1993-09-10 | 1995-03-16 | Eisai Co., Ltd. | Derives bicycliques heterocycliques d'ester sulfonique et de sulfonamide |
WO1999002501A1 (en) | 1997-07-09 | 1999-01-21 | Astra Pharmaceuticals Ltd. | Novel compounds |
JP2001233855A (ja) | 2000-02-25 | 2001-08-28 | Basf Ag | インドールタイプの化合物の製造方法 |
US20040019215A1 (en) | 2002-03-19 | 2004-01-29 | Kolb Hartmuth C. | Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates |
WO2004018428A1 (en) | 2002-08-23 | 2004-03-04 | Pharmacia & Upjohn Company Llc | Antibacterial benzoic acid derivatives |
WO2006016079A2 (fr) | 2004-07-13 | 2006-02-16 | Vichem | Procede perfectionne de fabrication d'acide phosphorique |
WO2006112549A1 (ja) | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
WO2007040289A1 (en) | 2005-10-05 | 2007-04-12 | Promeditech Inc. | Deformylase inhibitor, process for the preparation thereof, and composition comprising the same |
Non-Patent Citations (26)
Title |
---|
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, 2003, pages 197 - 209 |
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 19, 2004, pages 903 - 4906 |
EXPERIMENTAL CELL RESEARCH, vol. 74, 1972, pages 450 - 454 |
HELVETICA CHIMICA ACTA, vol. 87, 2004, pages 3131 - 3159 |
HETEROCYCLES, vol. 64, 2004, pages 475 - 482 |
HETEROCYCLES, vol. 68, no. 11, 2006, pages 285 - 99 |
JOURNAL OF ORGANIC CHEMISTRY, vol. 66, no. 5, 2001, pages 1919 - 1923 |
JOURNAL OF ORGANIC CHEMISTRY, vol. 68, no. 24, 2003, pages 9506 - 9509 |
JOURNAL OF ORGANIC CHEMISTRY, vol. 70, 2005, pages 6519 - 6522 |
JOURNAL OF ORGANIC CHEMISTRY, vol. 71, 2006, pages 167 - 175 |
JOURNAL OF THE AMERICA CHEMICAL SOCIETY, vol. 198, no. 48, 2006, pages 15374 - 75 |
KREAMER BL, IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, vol. 22, 1986, pages 201 - 211 |
LIVER TRANSPLANTATION, vol. 9, 2003, pages 278 - 284 |
NAT CHEM BIOL., vol. 1, 2005, pages 112 - 119 |
ORGANIC LETTERS, vol. 9, no. 3, 2007, pages 397 - 400 |
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 10, no. 3, 2006, pages 472 - 480 |
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 2, 1988, pages 214 - 220 |
SYNLETT, vol. 15, 2005, pages 2397 - 2399 |
SYNTHESIS, 2004, pages 59 - 61 |
TETRAHEDRON LETTERS, vol. 47, no. 36, 2006, pages 6485 - 6388 |
TETRAHEDRON, vol. 55, no. 34, 1999, pages 10271 - 10282 |
TETRAHEDRON, vol. 59, 2003, pages 1571 - 1587 |
TETRAHEDRON, vol. 60, 2006, pages 10983 - 10992 |
TETRAHEDRON, vol. 60, no. 48, 2004, pages 10983 - 10992 |
TETRAHYDRON LETTERS, vol. 28, no. 48, 1987, pages 6068 - 6072 |
WAHLBERG, J.A. ET AL., TRANSPLANTATION, vol. 43, 1987, pages 5 - 8 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11384115B2 (en) | 2004-10-25 | 2022-07-12 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
US10144759B2 (en) | 2004-10-25 | 2018-12-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
US10844089B2 (en) | 2004-10-25 | 2020-11-24 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
JP2010536845A (ja) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール化合物 |
JP2010536846A (ja) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 |
EP2493469A2 (en) * | 2009-10-26 | 2012-09-05 | LG Life Sciences Ltd | Pharmaceutical composition comprising indole compound |
JP2013508452A (ja) * | 2009-10-26 | 2013-03-07 | エルジー・ライフ・サイエンシーズ・リミテッド | インドール化合物を含む医薬組成物 |
US10322135B2 (en) | 2009-10-26 | 2019-06-18 | Lg Chem, Ltd. | Pharmaceutical composition comprising indole compound |
RU2557243C2 (ru) * | 2009-10-26 | 2015-07-20 | Эл Джи Лайф Сайенсиз Лтд. | Фармацевтическая композиция, содержащая индольное соединение |
CN102596198B (zh) * | 2009-10-26 | 2016-01-27 | 株式会社Lg生命科学 | 包含吲哚化合物的药物组合物 |
EP2493469A4 (en) * | 2009-10-26 | 2013-05-29 | Lg Life Sciences Ltd | PHARMACEUTICAL COMPOSITION WITH AN INDOIND CONNECTION |
CN102596198A (zh) * | 2009-10-26 | 2012-07-18 | 株式会社Lg生命科学 | 包含吲哚化合物的药物组合物 |
WO2011052950A3 (en) * | 2009-10-26 | 2011-11-24 | Lg Life Sciences Ltd. | Pharmaceutical composition comprising indole compound |
US9480692B2 (en) | 2011-04-06 | 2016-11-01 | Virginia Commonwealth University | Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
WO2015100312A1 (en) * | 2013-12-24 | 2015-07-02 | Virginia Commonwealth University | Uses of oxygenated cholesterol sulfates (ocs) |
EA032777B1 (ru) * | 2013-12-24 | 2019-07-31 | Вирджиния Коммонвелт Юниверсити | Способ предотвращения или лечения почечной недостаточности |
US10786517B2 (en) | 2013-12-24 | 2020-09-29 | Durect Corporation | Uses of oxygenated cholesterol sulfates (OCS) |
US10272097B2 (en) | 2013-12-24 | 2019-04-30 | Virginia Commonwealth University | Uses of oxygenated cholesterol sulfates (OCS) |
US11612609B2 (en) | 2013-12-24 | 2023-03-28 | Durect Corporation | Uses of oxygenated cholesterol sulfates (OCS) |
KR20230065387A (ko) * | 2013-12-24 | 2023-05-11 | 버지니아 커먼웰스 유니버시티 | 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도 |
KR102655918B1 (ko) | 2013-12-24 | 2024-04-09 | 버지니아 커먼웰스 유니버시티 | 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도 |
EP3107919A4 (en) * | 2014-02-20 | 2017-11-22 | University of Florida Research Foundation | Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment |
US11718645B2 (en) | 2014-02-20 | 2023-08-08 | University Of Florida Research Foundation, Incorporated | Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment |
US11406646B2 (en) | 2016-08-02 | 2022-08-09 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
WO2022220517A1 (ko) * | 2021-04-12 | 2022-10-20 | 주식회사 미토이뮨테라퓨틱스 | 줄기세포의 염증 또는 노화 억제용 조성물 및 이의 염증 또는 노화 억제 방법 |
Also Published As
Publication number | Publication date |
---|---|
US8349885B2 (en) | 2013-01-08 |
WO2009088192A3 (ko) | 2009-10-01 |
KR20090075638A (ko) | 2009-07-08 |
US20120270203A1 (en) | 2012-10-25 |
JP5188583B2 (ja) | 2013-04-24 |
WO2009088192A9 (ko) | 2009-11-19 |
CN101952281A (zh) | 2011-01-19 |
RU2460525C2 (ru) | 2012-09-10 |
JP2011509255A (ja) | 2011-03-24 |
KR101098583B1 (ko) | 2011-12-26 |
US20100291533A1 (en) | 2010-11-18 |
CN101952281B (zh) | 2014-04-02 |
EP2230238A4 (en) | 2012-11-07 |
EP2230238B1 (en) | 2013-12-11 |
EP2230238A2 (en) | 2010-09-22 |
RU2010132644A (ru) | 2012-02-10 |
BRPI0906612A2 (pt) | 2015-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009088192A9 (ko) | 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체 | |
AU2014260605B2 (en) | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | |
WO2010093191A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
WO2011043568A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
WO2014073904A1 (en) | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient | |
EP3116859A1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
AU2019310508B2 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | |
EP3681877A1 (en) | Pyrazole derivative compound and use thereof | |
WO2015102426A1 (en) | Novel indole derivative compound and pharmaceutical composition comprising the same | |
WO2016190630A1 (en) | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same | |
WO2015026172A1 (ko) | 세포괴사 저해제로서의 인돌아미드 화합물 | |
WO2012134188A2 (ko) | 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 | |
WO2018004065A1 (ko) | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
WO2010036000A2 (en) | Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof | |
WO2022108377A1 (ko) | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 | |
AU2019344240B2 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
WO2015026170A1 (ko) | 세포괴사 저해제로서의 인돌 화합물 | |
WO2021096335A1 (ko) | 신규한 퀴놀린 화합물 및 이의 용도 | |
WO2019039905A1 (ko) | 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물 | |
WO2022235091A1 (ko) | 신규한 헤테로사이클 화합물 및 이의 용도 | |
WO2018004066A1 (ko) | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
WO2022119362A1 (ko) | Gpx4 단백질 분해 유도 화합물 | |
WO2023191379A1 (ko) | 3,4-다이하이드로퀴녹살린-2-카복사미드 유도체 화합물 및 이를 포함하는 암 질환 예방 또는 치료용 약학적 조성물 | |
WO2022211573A1 (ko) | 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 | |
WO2024019597A1 (ko) | 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980104944.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09700417 Country of ref document: EP Kind code of ref document: A2 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 4009/CHENP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/007343 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12811525 Country of ref document: US Ref document number: 2009700417 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010541405 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010132644 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0906612 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100701 |